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Clostridium difficile is an increasingly common cause of nosocomial infection. C. 
difficile infection (CDI) presents as a spectrum ranging from asymptomatic carriage to 
mild diarrhoea, pseudomembranous colitis, toxic megacolon and intestinal perforation. It 
is not yet fully understood why this spectrum is seen, however, it is believed that the 
immune response mounted by an individual plays an important role in determining the 
outcome of infection. 
This thesis comprises three studies. Firstly, a comparative study of immune cell 
populations within the lamina propria of colonic tissue not exhibiting pathological 
changes and taken from individuals with symptomatic CDI (cases); asymptomatic 
carriers; and non-colonised controls. Effector T cells, B cells, plasma cells and 
macrophages were enumerated by means of immunohistochemical staining of tissue 
sections.   Secondly, a study to establish the prevalence within these three study groups 
of specific host single nucleotide polymorphisms (SNPs) in the TLR2, TLR5 and IL-8 
genes by PCR genotyping and to determine whether an association existed between 
these genotypes and susceptibility to CDI. Thirdly, an examination of the mechanisms of 
moxifloxacin resistance in a collection of clinical isolates. This study also sought to 
determine whether the competitive advantage conferred by resistance to moxifloxacin 
influenced the fitness of C. difficile isolates, in particular growth and the expression of 
the virulence factors toxins A and B.   
Carriers were found to have fewer of all four immune cell types quantified than both 
cases and controls. However, in only one instance, that of plasma cells, was this 
 ix
difference statistically significant. Cases had fewer of all cell types than controls but 
these differences were not significant. These findings suggest that individuals who 
become infected, both symptomatically and asymptomatically, with C. difficile display 
altered mucosal immune cell populations when compared with those of uninfected 
individuals.  
The data regarding host polymorphisms are suggestive of an association between the 
presence of SNPs and increased susceptibility to CDI. The variant IL-8 and TLR2 
genotypes were carried by cases and carriers while the variant TLR5 genotype was 
carried by cases only. No variant genotypes were present in control subjects.   
All moxifloxacin resistant isolates characterised in this study, with the exception of an 
isolate with intermediate resistance and a third-generation mutant with reduced 
susceptibility, carried the common gyrA mutation ACT→ATT (Thr82→Ile). Efflux 
pumps are known to play a role in multi-drug resistance in many bacterial species. Semi-
quantitative PCR analysis of expression of the putative efflux pumps cme and cdeA 
found no correlation between overexpression and moxifloxacin resistance, suggesting 
that these genes do not play a role. Three novel mutations in the putative promoter 
region of CD3197, a MerR family transcriptional regulator found immediately upstream 
of cme, were identified. No association between the presence of these mutations and 
overexpression of cme or resistance or sensitivity to moxifloxacin was found. The 
competitive advantage conferred by resistance to moxifloxacin does not influence the 
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1.1 The microorganism 
Clostridium difficile is a Gram-positive, anaerobic, spore-forming bacillus with a 
characteristic motility. Cultures have a characteristic odour, often described as 
resembling that of a barn yard or horse stable, and colonies exhibit chartreuse 
fluorescence when viewed under long wave UV light.  The organism was first 
isolated in 1935 from the commensal flora of neonates by Hall & O’Toole, who 
named it Bacillus difficilis reflecting the difficulties they had met in the process. 
They demonstrated that the organism was highly pathogenic in rabbits and guinea 
pigs due to its secretion of a soluble exotoxin. It was not until the 1970s, however, 
that an association with human disease was established. 
 
In 1974 Tedesco et al., evaluated 200 patients treated with clindamycin, 10% of 
whom were found to have a life-threatening condition known as pseudomembranous 
colitis (PMC) on endoscopy. This was of great concern to the medical profession as 
clindamycin was widely used to treat anaerobic infections. No pathogens were 
isolated from the plaque-like lesions seen in the colon. The first observation of a 
cytopathic toxin in the faeces of patients with PMC was reported by Larson et al., in 
1977; in the same year Rifkin et al., demonstrated that this cytopathic effect could be 
neutralised by Clostridium sordellii antitoxin.  The following year C. difficile was 
determined to be an aetiological agent of PMC (Bartlett et al., 1978; George et al., 
1978; Larson et al., 1978). Today C. difficile is the most common cause of 
nosocomial diarrhoea; it is widely thought to be the aetiological agent of some  
 2 
15-20% of cases of antibiotic-associated diarrhoea and almost all cases of PMC 
(Bartlett, 2002).  
 
1.2 Typing of isolates 
The ability to type isolates is crucial to an understanding of the epidemiology of any 
bacterial species and a number of techniques have been developed to type C. difficile, 
recently reviewed by Brazier (2001). Early techniques exploited phenotypic 
characteristics; however, since the 1980s the predominant methods have been 
genotype-based. 
 
1.2.1 Phenotypic methods 
The earliest methods were based on resistance patterns to antibiotics (Burdon, 1982), 
analysis of plasmids and soluble proteins (Wüst et al., 1982) and bacteriocin and 
bacteriophage typing methods (Sell et al., 1983). Immunochemical fingerprinting of 
EDTA-extracted cell surface proteins has also been used in outbreak studies (Poxton 
et al., 1984; Sharp & Poxton, 1985). 
 
Delmée et al., (1985) developed a serotyping scheme, based on the earlier work of 
Nakamura et al., (1981), able to distinguish 19 separate sero-groups. This method is 
still used as a reference for the comparison of other typing methods (Brazier, 2001).  
 
A novel method of typing, based on the variability in molecular mass of the high and 
low molecular weight surface layer (S-layer) proteins, has been developed in 
Edinburgh (McCoubrey & Poxton, 2001; McCoubrey et al., 2003).  
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1.2.2 Molecular methods 
Restriction enzyme analysis (REA) 
This method of typing involves the digestion of genomic DNA using the restriction 
enzyme HindIII, a frequent cutter (Clabots et al., 1993). The resulting bands are 
visualised in an agarose gel and compared by eye to existing exemplars. This method 
is highly reproducible and extremely discriminatory but time consuming and 
technically demanding (Brazier, 2001).  
 
Pulsed- field gel electrophoresis (PFGE) 
PFGE is another typing method that analyses genomic DNA by means of restriction 
digest. In this instance rare cutting enzymes, such as SmaI, are used. While this 
method is also highly discriminatory it is time consuming, costly and hindered in 
certain cases by DNA degradation (Brazier, 2001). However, Fawley & Wilcox 
(2002) report that the use of thiourea in both the agarose gel and electrophoresis 
buffer reduces the problem of degradation.   
 
Multilocus variable-number tandem-repeat analysis (MLVA) 
This is a recently developed PCR-based technique that amplifies seven regions 
featuring short tandem repeats distributed over the genome. Isolates are distinguished 
by analysis of repeat numbers (van den Berg et al., 2007). This method has been 
shown to differentiate serotypes, toxinotypes and ribotypes and their subtypes and 




Surface layer protein A gene sequence typing (slpAST) 
The slpA gene encodes the precursor of the S-layer proteins. Variable regions of the 
gene are amplified by PCR and analysed by way of restriction digest and DNA 
sequencing (Karjalainen et al., 2001). This method has been shown to discriminate 
types and subtypes. One advantage of such sequence-based techniques is the 
portability of the data (Killgore et al., 2008). 
 
Ribotyping 
It was reported in 1993 (Gürtler, cited in Cartwright et al., 1995) that the genome of 
C. difficile carried 14 copies of the rRNA gene, each with differing length intergenic 
spacer regions. Gürtler further demonstrated that variable numbers of different alleles 
were found in epidemiologically unrelated isolates. PCR amplification of the 
intergenic spacers generates differing numbers of fragments of variable size; these 
patterns permit so-called PCR ribotypes to be distinguished one from the other 
(Cartwright et al., 1995). Ribotyping is the typing method of choice in UK Anaerobe 
Reference laboratories; the approach currently used was adapted by O’Neill et al., 
(1996) from that devised by Cartwright et al., (1995). This technique is quick and 
discriminatory, at least at the ribotype level; subtyping of ribotypes requires the use 
of a more sensitive method (Brazier, 2001). 
 
Toxinotyping 
Toxinotyping was developed by Rupnik et al., (1998). It is premised on the existence 
of polymorphisms within the genes encoding toxins A and B. These polymorphisms 
are distinguished by PCR amplification of sections of each gene; the resulting 
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fragments are digested by restriction enzymes and the length of the products 
analysed by electrophoresis. While there is good correlation between this method and 
ribotyping, the latter is more discriminatory (Brazier, 2001).  
 
1.3 The ecology of C. difficile 
The spores of C. difficile are widely distributed in both the natural and built 
environment.  C. difficile has been isolated from sea, river, lake and swimming pool 
water, soil samples and the surface of raw vegetables (al Saif & Brazier, 1996). 
Studies have shown that spores are found throughout hospitals and nursing homes; 
amongst other areas organisms have been isolated from toilet seats, bedpans, floors, 
bedsheets, call buttons and feeding tube equipment (Cohen et al., 2000a; Fordtran, 
2006; Gerding et al., 1995) and portable commode chairs (McFarland et al., 1989). It 
has been demonstrated that increased levels of environmental contamination are 
associated with increased prevalence of hand carriage among health care workers, 
thus the hands of medical personnel can also be sites of contamination and potential 
sources of cross-transmission (McFarland et al., 1989; Samore et al., 1996).     
 
1.3.1 Food animals 
C. difficile colitis is now a common diagnosis in neonatal pigs (Songer, 2004) both in 
the USA and elsewhere. C. difficile has been associated with diarrhoea in calves but 
no causal relationship has yet been established (Rodriguez-Palacios et al., 2007b). 
The predominant toxinotype in both pigs and calves is toxinotype V, which is now 
being seen more frequently in human cases of C. difficile infection (CDI). In a three 
year period between February 2005 and February 2008 the incidence of ribotype 078, 
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toxinotype V organisms among clinical isolates in the Netherlands increased from 
3% to 13% (Goorhuis et al., 2008). Molecular analysis of human and porcine isolates 
revealed four clonal complexes containing both types of isolates. Similar findings 
were reported by Debast et al., (2009) and Jhung et al., (2008). Debast et al., 
concluded that the phenotypic and genotypic characteristics of ribotype 78, 
toxinotype V isolates from diarrhoeal pigs and human patients in the Netherlands 
were indistinguishable. In the study by Jhung et al., a high degree of molecular 
similarity between human and animal toxinotype V isolates was demonstrated. These 
findings suggest a common origin of human and animal strains or the possibility of 
transmission between species. Further evidence of this possible route of transmission 
is provided by the isolation of C. difficile from retail meat products; in many 
instances these isolates have been toxigenic (Rodriguez-Palacios et al., 2007a, 2009; 
Songer et al., 2009).  
 
1.3.2 Domestic pets 
Carriage rates of 23% in household pets (Borriello et al., 1983) and 39.5% among 
dogs and cats attending a veterinary clinic (Riley et al., 1991) suggest that pets may 
potentially be a reservoir of infection. Both studies isolated toxigenic and non-
toxigenic isolates. However, molecular analysis of animal and human isolates by 
O’Neill et al., (1993) found no correlation between pet isolates and those found in 





1.3.3 Neonates and children 
Carriage rates in healthy adults are typically 3 - 7% (Kato et al., 2001; Kelly & 
LaMont, 1998). By contrast carriage rates among neonates and children are much 
higher with the frequency of isolation from stools correlating with age. The carriage 
rate in neonates ranges from 52 – 64% (Enad et al., 1997; Holst et al., 1981; Larson 
et al., 1982), most individuals being asymptomatic carriers. In infants under two 
years of age the carriage rate varies between 4% and 60% with a greater number of 
individuals being symptomatic (Holst et al., 1981; McFarland et al., 2000).  The 
composition of the intestinal microbiota in early infancy is influenced by a number of 
factors. It has been shown that infants born by caesarean section are more often 
colonised with C. difficile and have lower numbers of bifidobacteria and Bacteroides 
spp than vaginally delivered infants (Penders et al., 2006). This study also 
demonstrated that exclusively bottle-fed infants are more often colonised with C. 
difficile than breastfed infants and that hospitalisation and prematurity are also 
associated with higher counts of C. difficile. The organism is usually acquired from 
the environment rather than the mother: Matsuki et al., (2005) demonstrated that 
children attending either a day-nursery or kindergarten were colonised with strains 
identical to those found on the floors of these facilities. A prospective study in a 
neonatal ward by Delmée et al., (1988) showed that most of the neonates were 







1.4 The disease 
 
1.4.1 Incidence of ribotypes among clinical isolates 
A prospective study of C. difficile infections in Europe (Barbut et al., 2007b) 
identified 66 different ribotypes, with 12 ribotypes (001, 002, 012, 014, 017, 020, 
027, 048, 077, 078, 126 and 168) accounting for 65.5% of isolates studied. The 
distribution of ribotypes varies greatly from country to country. The prevalence of 
the ribotype 027/North American pulsed-field 1/BI strain (the so-called 
“hypervirulent” strain) was 6.2%. As of 2008 this ribotype had been reported in 16 
European countries (Kuijper et al., 2008).  
 
Ribotypes 106 and 001 are the most common in Scotland.  In the three months to 
December 2008 these ribotypes comprised 34.8% and 23.2% respectively of the 
isolates typed by the Scottish Reference Laboratory. Ribotype 027 comprised 10.9%, 
with 078 comprising 2.7% (HPS C. difficile Working Group, 2009a).  
 
1.4.2 Nosocomial incidence  
A mandatory surveillance programme, under which episodes of CDI in patients aged 
65 and older are recorded, was introduced in Scotland in September 2006; 6,631 
cases were reported in the year to September 2008, an increase of 0.1% on the year 
to September 2007 (HPS C. difficile Working Group, 2009b).  
 
In England mandatory reporting of cases in patients aged 65 and older has been in 
place since January 2004. There was a steady increase in cases in this age group 
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between 2000 and 2006, peaking at 55,635 in the latter year, with a small decrease 
(9%) seen in 2007 (Health Protection Agency, 2009). Mandatory surveillance for the 
2-64 years age group was introduced in April 2007. In the year to March 2008, 
infections in this age group accounted for 18% of the reported total.  
 
1.4.3 Risk factors for nosocomial disease 
A systematic review by Bignardi (1998) of published data highlighted frequently 
identified risk factors for CDI including: severity of co-morbidity; increasing age; 
duration of hospital stay; the duration of courses of antibiotics; the use of multiple 
antibiotics; nasogastric intubation; and the use of gastric acid suppressants.  
 
Antibiotics 
Previous treatment with antibiotics is widely acknowledged as a key risk factor, 
principally due to disruption of the native gut flora and hence the protection this flora 
provides against enteric pathogens. In the absence of such disruption C. difficile is 
unable to colonise the gut. Borriello & Barclay (1986) demonstrated that faecal 
emulsions containing viable organisms taken from healthy adult volunteers inhibited 
the growth of C. difficile; emulsions taken from patients receiving antibiotics had a 
reduced ability to inhibit growth. Similarly, caecal emulsions taken from 
clindamycin-treated hamsters did not display the inhibitory capabilities of emulsions 
from untreated hamsters (Borriello & Barclay, 1986). Clindamycin (Tedesco et al., 
1974) and β-lactamase-susceptible β-lactams (Starr et al., 2003; Tedesco, 1975) are 
most commonly associated with CDI. However, most antibiotics, particularly oral 
antibiotics, have the potential to induce disease (Bartlett, 1992). The use of 
 10 
clindamycin has declined since the 1970s and from the late 1980s the use of 
cephalosporins, in particular third-generation drugs, has carried the highest risk of 
CDI (Baxter et al., 2008; Gerding, 2004). Starr et al., (2003) found that the use of 
third-generation cephalosporins increased the risk of an individual becoming culture-
positive. This study also showed that an individual’s risk of becoming toxin-positive 
increased with the use of antibiotics, particularly amoxicillin and cephalosporins 
other than ceftriaxone. More recently, attention has turned to a possible role for 
fluoroquinolones in the aetiology of CDI. In a recent review Deshpande et al., (2008) 
concluded that the data are suggestive of an association between fluoroquinolone use 
and CDI, in particular that caused by the 027 ribotype, but are not yet conclusive. 
Gerding (2004) suggests that frequent fluoroquinolone use in hospitals could be 
increasingly responsible for outbreaks of CDI for two reasons. Firstly, the newer 
fluoroquinolones have greater activity against anaerobes and are therefore more 
likely to disrupt normal flora. Secondly, they may exert selective pressure favouring 
the emergence of fluoroquinolone-resistant strains during antibiotic treatment and the 
subsequent proliferation of resistant clones. 
 
Age 
Nosocomial CDI is principally a disease of older individuals (65 years and above) 
(Al-Eidan et al, 2000; Asha et al., 2006; Karlström et al, 1998; Kyne et al., 1999;  
McFarland et al., 1995; McFarland et al., 1990; Starr et al., 2003). This susceptibility 
likely stems from the increased probability in this population of serious co-
morbidity, greater exposure to antibiotics and longer periods spent in hospitals, all 
identified risk factors (Bignardi, 1998). Colonisation resistance provided by gut 
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commensal flora is also reduced in the elderly (Borriello & Barclay, 1986; Hopkins 
& McFarlane, 2002).  
 
Clinical procedures and treatments 
Administration of antineoplastic drugs (Halim et al., 1997) and diuretics (Raveh et 
al., 2006) has been associated with CDI. Clinical procedures associated with 
increased risk of CDI include: the placement of nasogastric tubes (Asha et al., 2006; 
Bliss et al., 1998; Kyne et al., 1999); administration of enemas (McFarland et al., 
1990); and endoscopy and gastrointestinal surgery (Kyne et al., 1999; McFarland, 
1998; Spencer, 1998).  
 
Gastric acid suppressants 
Suppression of the production of gastric acid by proton pump inhibitors (PPIs) and 
H2 blockers, resulting in the loss of an innate defence mechanism against ingested 
pathogens, has been recognised as a risk factor for CDI by certain studies (Aseeri et 
al., 2008; Choudhry et al., 2008; Cunningham et al., 2003; Dial et al., 2004, 2005). 
However, Wilcox et al., (2008) found that prior exposure to PPIs or H2 antagonists 
was not significantly more common in CDI cases. The study by Choudhry et al., 
(2008) reported that valid indications for the prescribing of PPIs could not be 
identified in 63% of the patients; it has been suggested that reducing the unnecessary 
use of PPIs may help reduce incidence of CDI. 
 
A recent meta-analysis by Garey et al., (2008) highlighted risk factors for recurrent 
CDI. They found that continued use of non- C. difficile treatment antibiotics after a 
 12 
diagnosis of CDI, concomitant administration of gastric acid suppressants, and older 
age were significantly associated with increased risk of recurrent CDI.  
 
Co-morbidity 
A number of studies have demonstrated an association between susceptibility to CDI 
and underlying morbidity. Harbarth et al., (2001) showed an association with the 
presence of gastrointestinal disease, anaemia and renal disease. CDI has also been 
reported in HIV-positive patients (Tumbarello et al., 1995) and individuals with 
leukaemia (Milligan & Kelly, 1979). Patients with Crohn’s disease and ulcerative 
colitis (collectively known as inflammatory bowel disease) have developed CDI in 
the absence of antibiotic exposure albeit CDI is more common when antibiotics have 
been administered (Greenfield et al., 1983).  
 
Wilcox & Fawley (2007) reported a correlation between CDI and viral 
gastroenteritis, with rates for CDI found to be higher in units affected by norovirus 
outbreaks. The reason for this association is unclear: it could result from an increase 
in the risk of transmission of C. difficile or it is possible that norovirus infection 
perturbs the commensal flora allowing colonisation by C. difficile.  
 
1.4.4 Community-acquired CDI and the emergence of disease in previously 
low risk groups 
CDI is classically regarded as a nosocomial infection. However, there is growing 
evidence of the importance of the community as a source of infection. Community-
acquired CDI is defined by The European Centre for Disease Prevention and Control 
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as the onset of symptoms outside a health care facility with the patient not having 
been discharged from a health care facility within 12 weeks of symptom onset; or the 
onset of symptoms within 48 hours of admission to a health care facility with the 
patient having no prior stay in a health care facility in the 12 weeks preceding 
symptom onset (Kuijper & van Dissel, 2008). It is of note that community-acquired 
CDI is being reported in populations not previously thought to be at risk and in many 
cases there is no link with known risk factors.   
In a retrospective study in North Carolina Kutty et al., (2008) found that 34% 
(208/604) of patients with community-onset CDI met this definition of community-
acquired disease. In Connecticut, a 2006 surveillance study reported an annual 
incidence of 6.9 cases of community-acquired CDI per 100,000 population (CDC, 
2008). Of 241 patients, 59 (25%) had no underlying conditions and no exposure to 
inpatient health care in the preceding 12 months. Compared with the other patients 
this group was younger, 63% being aged 45 or younger, and in 21 (36%) cases there 
was no history of antimicrobial use in the previous three months. Wilcox et al., 
(2008) undertook a prospective case-control surveillance study of community-
derived faecal samples and reported that 2.1% of randomly selected faecal samples 
were positive for C. difficile cytotoxin. Of the 42 case patients detected 26 (62%) 
were aged 65 or younger. Exposure to antibiotics in the four weeks prior to testing 
was significantly more frequent among cases than controls and hospitalisation in the 
previous six months was seen to be significantly associated with CDI. However, 
there was no history of antibiotic use in the month before toxin detection in almost 
half the cases and approximately one-third had not been exposed to antibiotics or 
been recently hospitalised. Similar findings were reported by Dial et al., (2008) in 
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their case-control study of patients aged 65 years or older admitted to hospital with 
community-acquired CDI. Approximately half of the cases had no exposure to 
antibiotics in the three months preceding admission.  
 
Reports are now emerging of CDI cases among peripartum women, historically 
considered a low risk group. Ten such cases were identified in four US states in the 
period 2003-2005 (CDC, 2005). Of these 10 patients, 40% required hospitalisation 
and one died. Rouphael et al., (2008) identified 10 cases in a one year period from 
2005-2006. Nine patients had a history of antibiotic use in the three months prior to 
diagnosis and three had been hospitalised. Six patients were admitted to intensive 
care and death occurred in three instances.  
 
The significance of C. difficile among the paediatric population has been the subject 
of debate for many years given that asymptomatic carriage among infants is not 
uncommon. Recent data, however, suggest that cases of CDI among children are 
increasing. A study by Benson et al., (2007) in a children’s hospital in Washington 
D.C. reported that the number of cases of community-acquired CDI presenting in the 
emergency room increased from 1.18 cases per 1,000 visits in 2001 to 2.47 cases per 
1,000 visits in 2006. Sixty one percent of children with a toxin-positive stool sample 
were aged 2 years or older. Kim et al., (2008) examined the annual incidence of CDI 
between 2001 and 2006 among in-patient children in 22 American children’s 
hospitals. Over the study period, it increased from 2.6 to 4.0 cases per 1,000 
admissions, with the median age of affected children being 4 years.  Data for 2006 
for the Lothian University Hospitals Trust showed 10.4 episodes of CDI per 10,000 
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inpatient days in the 0-18 age group, with 6.0 episodes of CDI per 10,000 inpatient 
days in the 0-13 age group (Reddy, personal communication).  
 
1.4.5 Costs of CDI 
CDI is responsible for a substantial economic burden. The acquisition of CDI in 
hospital usually results in an increased length of stay and a concomitant increase in 
direct hospital costs. In a study of an American tertiary care hospital, Song et al., 
(2008) reported an additional stay of five and a half days carrying a cost of $6,326 
(£4,258) per case. In a similar study in Germany, Vonberg et al., (2008b) reported an 
additional stay of seven days incurring an additional cost of €7,147 (£6,099).  
 
1.4.6 Outcomes of infection 
Following colonisation with toxigenic C. difficile individuals may become 
asymptomatic carriers or develop disease. The carriage rate among healthy adults is 
typically 3 - 7% (Kato et al., 2001; Kelly & LaMont, 1998) but is higher among 
hospitalised individuals and those in long-term care facilities. McFarland et al., 
(1989) reported that 21% of patients whose stools were culture-negative on 
admission acquired C. difficile during their hospital stay and of these individuals 
63% remained asymptomatic, giving a carriage rate among this group of 
approximately 13%.  Riggs et al., (2007) reported that the carriage rate among 
asymptomatic individuals during an outbreak in a care facility was 51%. The 
spectrum of clinical features seen in those who develop disease ranges from mild 
diarrhoea to PMC. Patients with severe disease commonly present with abdominal 
pain, profuse diarrhoea (frequently non-bloody), leucocytosis, nausea, fever, 
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anorexia and malaise (Monaghan et al., 2008). On occasion patients may present 
with toxic megacolon or perforation, further severe complications of CDI, with no 
history of diarrhoea (Bartlett, 1992). Recurrent disease occurs in between 15% and 
35% of patients with CDI, reflecting either the persistence of the original strain or re-





1.5.1 Clinical diagnosis 
The presentation of an individual with diarrhoea and other characteristic symptoms 
after treatment with antibiotics, together with the characteristic nature of the stools 
can be used to diagnose CDI accurately (Wilcox, 2007). The use of flexible 
sigmoidoscopy (with biopsies) has been proposed for those patients suspected to 
have CDI but who have toxin-negative stools (Johal et al., 2004a). PMC can be 
quickly diagnosed by endoscopic examination.  
 
1.5.2 Laboratory diagnosis 
This most commonly takes the form of toxin detection in stools. Many laboratories 
use commercially produced enzyme-linked immunosorbent assays (ELISAs) to 
detect toxin A or toxins A and B. It is preferable to use a test that detects both toxins 




 strains that cause clinical symptoms. Stool samples may 
also be cultured on selective media such as CCEY which contains cycloserine, 
cefoxitin, egg yolk, lysed blood and sodium cholate to encourage the germination of 
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spores (Brazier, 1993). The organism is identified by colony morphology, odour, and 
fluorescence under UV light (Brazier, 1993). Due to the three to four day delay in 
obtaining a diagnosis, culture is not routinely carried out in hospital laboratories. It 
is, however, extremely valuable in investigating outbreaks as isolates can be 
characterised.  A recently introduced assay for the detection of the glutamate 
dehydrogenase antigen (C.Diff Chek-60; TechLab) has proved to have a very high 
negative predictive value. However, due to its modest positive predictive value it is 
necessary to couple its use with a further confirmatory test such as the tissue culture 
cytotoxicity neutralisation assay. This increases the cost and time involved in testing 
and its use is unlikely to be widely accepted until a more cost-effective, rapid second 
test is introduced (Gilligan, 2008).  A commercial real-time PCR assay (BD 
GeneOhm Cdiff) amplifying tcdB has been available since 2007 and its first 
evaluations have been recently published (Barbut et al., 2009; Stamper et al., 2009). 
The assay was found to be a more rapid (less than 3 hours) and more sensitive 
method than the tissue culture cytotoxicity neutralisation assay.  
 
1.6 Treatment 
1.6.1 Initial episode 
Cessation of precipitating antibiotic treatment 
In those with a mild case of CDI, stopping the precipitating antibiotic may be enough 
to resolve the problem. In a prospective randomised trial of metronidazole against 
vancomycin, diarrhoea resolved in 22.8% of patients in the 48-72 hour period before 
they were recruited into the study (Teasley et al., 1983). In a more recent prospective 
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study (Johal et al., 2004a) 30% of patients saw their diarrhoea resolve in a median 
period of 4 days post-cessation of precipitating antibiotic.  
 
Antimicrobial treatment  
In controlled clinical trials vancomycin, metronidazole, bacitracin, fusidic acid and 
teicoplanin have been shown to be effective in the treatment of CDI (Nelson, 2007). 
The most commonly prescribed treatments are oral metronidazole and oral 
vancomycin (Gerding et al., 2008b). Until recently studies suggested there was little 
to choose between them in terms of patient response or recurrence rates (Teasley et 
al., 1983; Wenisch et al., 1996), although vancomycin has a quicker response time 
(Wilcox & Howe, 1995). It has now been reported (Zar et al., 2007) that vancomycin 
is superior for the treatment of severe CDI. Reduced susceptibility to metronidazole 
among clinical isolates has been reported (Baines et al., 2008) but the implications 
for clinical practice are not yet clear.  
 
1.6.2 Relapses and recurrences 
The risk of recurrent disease is higher in individuals who have had more than one 
episode of CDI (Kelly et al., 1994) and it poses a therapeutic challenge. The use of 
tapered and pulsed regimens of vancomycin has been demonstrated to be beneficial 
(McFarland et al., 2002). In an uncontrolled study by Johnson et al., (2007) rifaximin 
given immediately after vancomycin treatment prevented predictable recurrences in 




1.6.3 Role of surgery 
Indications for surgery include toxic megacolon, perforation and failure to respond to 
medical therapies. Post-operative mortality rates are often high (Longo et al., 2004; 
Synnott et al., 1998). 
 
1.6.4 Alternative therapies 
Treatment alternatives to metronidazole and vancomycin are being keenly sought.  
 
New antimicrobials 
Agents under investigation include nitazoxanide, rifaximin and ramoplanin 
(Monaghan et al., 2008). OPT-80, a macrocyclic antibiotic, was recently reported to 
resolve mild to moderate diarrhoea in 91% of cases in a phase 2 clinical trial (Louie 
et al., 2009). A one month recurrence rate of 5% was noted.  
 
Probiotics 
Treating CDI through the replacement of disrupted intestinal flora by administration 
of probiotic organisms is intrinsically attractive. However, a recent systematic 
Cochrane review of published data (Pillai & Nelson, 2008) found that only one study 
reported a statistically significant benefit in the treatment of CDI. McFarland et al., 
(1994) found that patients receiving Saccharomyces boulardii were significantly less 
likely to experience recurrences than patients receiving placebo. Pillai & Nelson 
concluded that there is insufficient evidence to recommend probiotic therapy as an 
adjunct to antibiotic therapy for CDI and that there is no evidence to support the use 
of probiotics alone in its treatment. 
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Immunotherapy 
Case reports have indicated that the use of intravenous human immunoglobulin 
(IVIG) in patients with severe CDI is beneficial (McPherson et al., 2006; Salcedo et 
al., 1997).  However, a small pair-matched study by Juang et al., (2007) revealed no 
difference in clinical outcome between those treated with IVIG and those not.  
 
Non-toxigenic strains 
Sambol et al., (2002) demonstrated that colonisation of the gut with non-toxigenic C. 
difficile (NTCD) post-administration of clindamycin protected hamsters after 
challenge with a toxigenic strain. The use of NTCD to prevent recurrent disease in 
humans will shortly be clinically trialled (ViroPharma Inc.). The aim of this therapy 
is to colonise the gut of patients treated for initial episodes of CDI with NTCD to 
prevent re-infection by toxigenic strains. 
 
Toxin binding compounds 
Treatment with these compounds is based on the assumption that preventing 
interaction between toxins and host cells will mitigate damage. Colestipol and 
cholestyramine, both anion-exchange resins, bind C. difficile toxins but no clinical 
efficacy has been demonstrated (Aslam et al., 2005).  
 
Tolevamer, the salt of an anionic polymer, binds both toxins A and B. Phase II 
clinical trials demonstrated non-inferiority to vancomycin for treatment of mild to 
moderate CDI (Louie et al., 2006). However a study demonstrated that Tolevamer 
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failed to neutralise cytotoxicity in a human gut model, reflecting the poor efficacy 
seen in recent phase III trials (Baines et al., 2009). 
 
Vaccines 
The use of a vaccine containing toxoids A and B has been reported in a study of three 
patients with recurrent CDI (Sougioultzis et al., 2005). In the six months following 
vaccination no further episodes of CDI were reported. Sanofi Pasteur is presently 




The use of healthy donor stools, administered as an enema or via nasogastric tube, to 
replace a patient’s microbiota has met with some success. Aas et al., (2003) reported 
in a retrospective review that 15 of 18 patients with recurrent CDI remained relapse 
free 90 days post-“transplant”.  
 
1.7 Control and prevention of CDI in health care facilities 
 
Two interventions have been shown to be effective at reducing transmission during 
outbreaks of CDI: disinfection with 10% hypochlorite solution to reduce 
environmental contamination and use of barrier precautions (particularly gloves) by 
health care workers (Gerding et al., 2008a). It is important that all surfaces 
commonly contaminated by spores are cleaned appropriately. Isolation or cohorting 
of patients with CDI and good hand hygiene practices by health care workers and 
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visitors in contact with patients is recommended.  Exposure to antibiotics is a very 
important predisposing factor in CDI and their prudent use should be promoted as 
standard in attempts to prevent and control CDI (Vonberg et al., 2008a). A recent 
Cochrane analysis (Davey et al., 2005) indicated that hospital-acquired infections, in 
particular CDI, can be reduced by improvements in antibiotic prescribing. Effective 
antimicrobial stewardship programmes restrict the use of high-risk antibiotics, reduce 
polypharmacy and long-term therapy and advocate avoidance of inappropriate 
prescribing (Vonberg et al., 2008a).  
 
1.8 Virulence factors 
 
1.8.1 The pathogenicity locus (PaLoc) 
The PaLoc is a 19.6kb region of the chromosome, present in only one copy and at the 
same site in all strains of C. difficile (Braun et al., 1996). It encodes five genes: toxin 
A (tcdA); toxin B (tcdB); tcdC; tcdR and tcdE (Figure 1.1). A pathogenic strain is 
defined as one that produces at least one of the two toxins. In non-pathogenic strains 
the PaLoc is absent (Cohen et al., 2000b). Sequences at either side of the PaLoc are 
conserved in all strains suggesting that this region may be a distinct genetic element, 
albeit one that is not mobile (Braun et al., 1996).  
                              
  
 Figure 1.1.  Schematic representation of the PaLoc (adapted from Matamouros et al., 2007). 
tcdR tcdB tcdE tcdA tcdC 
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As discussed in section 1.2.2 the method of toxinotyping can be used to differentiate 
between strains. Strains which carry a PaLoc identical to that of reference strain 
VPI10463 are known as toxinotype 0; currently 24 variant toxinotypes (I – XXIV) 
are known (Rupnik, 2008). In addition to these toxin-gene-variants toxin-production-
variants have been identified, characterised by the production of toxin B only or by 






strains were the first well-characterised variant strains (Borriello et al., 1992; 
Depitre et al., 1993; Lyerly et al., 1992). The A-B+ phenotype is currently associated 
with four toxinotypes: VIII, X, XVI and XVII, with the majority of strains being of 
toxinotype VIII (Rupnik, 2008). In this toxinotype the lack of TcdA production 
stems from the presence of a nonsense mutation introducing a stop codon in tcdA 
(von Eichel-Streiber et al., 1999). Until recently it was thought that both toxins were 
required to cause disease, however outbreaks of CDI caused by A-B+ strains are 
being reported more frequently, undermining this belief (al-Barrak et al., 1999; 
Johnson et al., 2001; Kuijper et al., 2001; Limaye et al., 2000).  
 
1.8.2 The mechanism of action of toxins A and B 
Toxins A and B, considered the main virulence factors of C. difficile, are part of a 
group of toxins referred to as “Large Clostridial Toxins” (LCTs). Toxins A and B are 
exotoxins which are taken up from the gut lumen by enterocytes. Initial investigation 
of the toxins suggested that only toxin A was enterotoxic. Both are cytotoxic in cell 
cultures although toxin B is 100 to 1000 times more potent in this regard than toxin 
A; toxin B is therefore referred to as the cytotoxin and toxin A as the enterotoxin, 
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inducing diarrhoea (Schirmer & Aktories, 2004). Data from animal work (Corthier et 
al., 1991; Kurtz et al., 2001) led to the proposal that toxin A is the major pathogenic 
toxin in CDI, however, a recent study by Lyras et al., (2009) provides evidence that 
toxin B is the more important of the two. This group produced tcdA and tcdB mutants 
in which the separate toxin genes were inactivated and the virulence of the mutants 
tested in the hamster model of disease. It was found that tcdA mutants remained fully 
virulent, while the tcdB mutants had an attenuated virulence phenotype.  
 
Toxins A and B have very similar molecular weights, amino acid sequences and 
enzymatic activity; both glucosylate small GTPases (Voth & Ballard, 2005). They 
have three regions: the N-terminal catalytic domain; the C-terminal toxin receptor-




Figure 1.2. The structure of toxin B (taken from Schirmer & Aktories, 2004). 
 
Binding to the toxin receptor  
The C-terminal binding domain is composed of repetitive oligopeptide elements, 
known as CROPs, which are regarded as host cell surface polysaccharide-binding 
motifs (Just & Gerhard, 2004).  The receptors for the LCTs are believed to be 
nonproteinaceous. TcdA has been shown to bind to a disaccharide present on the I, X 
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and Y antigens found on a variety of human cells (Tucker & Wilkins, 1991). TcdB 
has been shown to bind to a number of different cell types although its receptor 
remains unidentified (Voth & Ballard, 2005). Toxin-receptor interaction induces 
receptor-mediated endocytosis (Just & Gerhard, 2004). 
 
Membrane translocation 
Translocation of the toxins into the cytosol requires acidification of the early 
endosome. Barth et al., (2001) demonstrated that inhibition of toxin B cytotoxicity 
resulted from treatment of cells with a proton pump inhibitor. Furthermore, if the 
medium was acidified the toxin could be taken up directly into the cytosol in spite of 
the presence of the inhibitor. In response to the lowered pH in the endosome the 
toxins undergo a conformational change, exposing hydrophobic domains (Qa’Dan et 
al., 2000) which facilitate interaction with the endosomal membrane (Barth et al., 
2001). The question of whether the full toxin B or the enzymatic domain alone is 
translocated into the cytosol was recently answered by Pfeifer et al., (2003). A 
number of techniques were used to demonstrate that the C-terminal remained in the 
endosome while the N-terminal was located in the cytosol. The toxin is 
autocatalytically cleaved by a cysteine protease activated by inositol 
hexakisphosphate (Egerer et al., 2009).  
Enzymatic activity 
The cytosolic targets of TcdA and TcdB are the proteins of the Rho and Ras families 
(Just et al., 1995a, 1995b). These proteins belong to a superfamily of low molecular 
mass GTPases which act as molecular switches in a large number of signalling 
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pathways. The GTPases alternate between an inactive, GDP-bound form in the 
cytosol and an active, GTP-bound form at the cell membrane. In the cytosol the Rho 
proteins bind the guanine nucleotide dissociation inhibitor (GDI), this appears to 
prevent nucleotide exchange. The GTPases translocate to the cell membrane 
following receptor-mediated activation; here GDP is exchanged for GTP in a process 
catalysed by guanine exchange factors (GEFs). GTP is subsequently hydrolysed to 
GDP by members of the GTPase activating proteins family (GAPs) returning the 
GTPase to its inactive form (Schirmer & Aktories, 2004). Both TcdA and TcdB 
glucosylate the target protein by transferring a sugar moiety to threonine-37 of the 
GTPase using the co-substrate UDP-glucose (Just et al., 1995a, 1995b), resulting in 
the GTPase’s inactivation. Cycling of the Rho proteins under normal circumstances 
and the points of action of TcdA and TcdB are shown in Figure 1.3. 
 
Figure 1.3. Glucosylation of GTPases by TcdA and TcdB (taken from Schirmer & Aktories, 2004). 
Glucosylation by toxins A and B (LCC) blocks the coupling of Rho-GTPases with effector molecules 
(1); inhibits GEF-catalysed nucleotide exchange (2); blocks the Rho/GDI interaction (3); inhibits GTP 
hydrolysis activated by GAPs (4).  
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The glucosyltransferase activity is thought to result from the presence of a DXD 
(aspartate-X-aspartate) motif in the enzymatic domain (Busch et al., 1998). 
 
Effects of glucosylation on the functioning of GTPases  
Rho GTPases regulate a number of different processes within the cell, hence their 
glucosylation results in a range of effects.  Lethal depolymerisation of the actin 
cytoskeleton resulting in the typical rounding phenotype known as CPE (cytopathic 
effect) is prominent amongst these. Inactivation of the GTPases also results in the 
breakdown of maintenance of tight junctions within the colonic epithelial barrier. 
This increases the permeability of the epithelial layer, resulting in diarrhoea (Voth & 
Ballard, 2005). Neutrophils pass through the opened junctions and their presence in 
the lumen, together with mucus, fibrin and inflammatory cells released by 
inflammatory ulcers, contributes to the formation of a pseudomembrane (Thelestam 
& Chaves-Olarte, 2000). Cell apoptosis is an additional consequence of the 
glucosylation of GTPases (Calderon et al., 1998; Zhao et al., 2003). 
 
The process of cellular intoxication, glucosylation and its effects on the Rho proteins 










Figure 1.4. Representation of toxin entry, glucosylation and its effects on the Rho proteins (taken 






TcdR was proposed to be a positive regulator of the production of toxins A and B by 
Hundsberger et al., (1997). Mani & Dupuy (2001) showed that TcdR acted as an 
alternative sigma factor that bound to the RNA polymerase core enzyme and 
activated transcription of tcdA and tcdB by mediating the binding of the enzyme to 
the toxin genes’ promoters.  
 
1.8.4 TcdC 
Analysis of the transcription of the PaLoc (Hundsberger et al., 1997) demonstrated 
that tcdC is transcribed divergently from the remainder of the genes and is highly 
expressed during exponential phase, with transcription shut off as the cells enter 
stationary phase. This pattern is the reverse of that seen in transcription of the toxin 
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genes and tcdR, suggesting that TcdC is a negative regulator of toxin gene 
expression. Evidence supporting this suggestion has been provided by Matamouros 
et al., (2007) and Dupuy et al., (2008). It was shown that TcdC destabilises the RNA 
polymerase-TcdR complex, preventing it from recognising and binding the tcdA and 
tcdB promoters and thus inhibiting toxin gene expression. 
 
1.8.5 TcdE  
The tcdE gene is co-transcribed with tcdA and tcdB; it encodes a hydrophobic protein 
homologous to the cytolytic holin proteins of bacteriophages (Tan et al., 2001). This 
group demonstrated that TcdE acts at the cell membrane and that the expression of 
tcdE in Escherichia coli resulted in lysis of the bacterial cells unrelated to 
environmental factors. These findings prompted the suggestion that TcdE functions 
in the formation of membrane lesions that permit the release of toxins A and B into 
the environment. It is known that TcdA and TcdB lack a signal sequence mediating 
trafficking to the cell membrane and are thus likely to accumulate in the cytoplasm 
(Aktories, 1997). Why secretion of toxins is associated with bacterial cell death is 
unknown although it has been shown that toxin release correlates with sporulation 
and the survival of the organism in this form (Kamiya et al., 1992).  
 
1.8.6 Expression of the PaLoc 
Hammond et al., (1997) studied expression of the PaLoc by hybridisation of gene-
specific probes with RNA transcripts. The data suggested a model in which the 
PaLoc is transcribed as a 17.5kb polycistronic transcript comprising tcdA, tcdB, tcdR 
and tcdE. It was shown that the transcript of tcdA was immediately processed while 
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that of tcdB formed part of a second processing intermediate along with the 
transcripts of tcdR and tcdE. Furthermore it was posited that tcdA and tcdB were also 
transcribed monocistronically. Further evidence of this mode of transcription was 
provided by Hundsberger et al., (1997). They demonstrated that the PaLoc is 
organised with several promoters that control the simultaneous transcription of 
monocistronic transcripts of tcdA and tcdB and polycistronic transcripts of all four 
genes.   
 
Regulation of transcription is multi-factorial. CodY, a global regulator of gene 
expression in low G+C Gram-positive bacteria, has been shown to repress toxin gene 
expression in C. difficile. Dineen et al., (2007) demonstrated that inactivating the 
codY gene resulted in the derepression of the five genes of the PaLoc during 
exponential and stationary phases. CodY was found to bind to the tcdR promoter 
region with high affinity suggesting that regulation of toxin gene expression by this 
protein is mediated by direct control of tcdR expression. CodY was also found to 
bind with high affinity to the likely promoter region of tcdC. It is not known why 
CodY would repress both the positive and negative regulators of toxin gene 
expression. Binding to the tcdR promoter was enhanced in the presence of certain 
amino acids and GTP indicating a possible link between nutrient limitation and 
PaLoc expression.  
 
The possibility of regulation by quorum sensing has been raised by the finding within 
the C. difficile strain 630 genome of the luxSCd
 
gene which encodes an AI-2 synthase 
and is primarily expressed in late exponential phase (Carter et al., 2005). This gene is 
conserved in pathogenic and non-pathogenic strains (Lee & Song, 2005) and is 
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preceded by two genes known as rolA and rolB encoding proteins with similarities to 
bacterial two-component signalling systems (Carter et al., 2005). The involvement of 




1.8.7 Environmental regulation of the PaLoc 
Toxin production is well known to be regulated by environmental factors. It is highly 
dependent on temperature (Karlsson et al., 2003); maximal yields are seen at 37°C 
with low production at 22°C and 42°C.  The presence in the growth medium of 
amino acids, in particular proline, cysteine and cysteine derivatives, down-regulates 
toxin production (Karlsson et al., 1999, 2000). Thioglycollate does not impact upon 
toxin production, indicating that the effect of cysteine on toxin production is not 
mediated by changes in redox potential (Karlsson et al., 2000). A coupling between 
toxin expression and up-regulation of enzymes involved in alternative energy 
metabolism, such as the use of butyrate or succinate, has been demonstrated 
(Karlsson et al., 2000, 2008). It appears these pathways may be simultaneously 
altered by the presence of certain amino acids. Increasing concentrations of glucose 
in the growth medium reduces transcription of tcdA and tcdB, being completely 
repressed at 1% (Dupuy & Sonenshein, 1998). It has been hypothesised that glucose 
acts indirectly by preventing the exhaustion of certain amino acids, the presence of 
which represses toxin production (Karlsson et al., 2008).  
 
Reducing the concentration of biotin in the growth medium reduces growth and 
increases toxin production (Yamakawa et al., 1996). Conversely, an excess of biotin 
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inhibits the production of toxin while increasing growth (Yamakawa et al., 1998). It 
has been suggested that biotin levels in the gut could be reduced as a result of the 
disruption of the commensal flora, triggering toxin production (Yamakawa et al., 
1996). The effects on growth and toxin production of adding amino acids to a growth 
medium in which biotin is limited differ between amino acids (Yamakawa et al., 
1998). The presence of lysine, asparagine, glutamine and glutamic acid repress toxin 
production. Growth is enhanced by the presence of asparagine, glutamine and 
glutamic acid and inhibited by lysine.  
 
1.8.8 Antibiotics and expression of the PaLoc 
The role of antibiotics in the pathogenesis of CDI through the impairment of 
colonisation resistance has already been discussed. A number of studies suggest that 
subinhibitory levels of antibiotics may further contribute to pathogenesis by 
influencing the production of toxins. Onderdonk et al., (1979) showed that sub-MIC 
concentrations of penicillin and vancomycin increased toxin production, while 
Honda et al., (1983) reported a toxin-inducing effect for cephalosporins and 
clindamycin. Drummond et al., (2003b) demonstrated that sub-MIC concentrations, 
particularly of metronidazole, clindamycin and amoxicillin, induced toxin production 
earlier than was seen in antibiotic-free medium. Similar findings were reported by 
Gerber et al., (2008). Strains exposed to sub-MIC levels of metronidazole, 
vancomycin, clindamycin and linezolid showed earlier toxin production. The 
transcription rate of toxin genes was increased by exposure to all antibiotics used 
apart from clindamycin. Similar findings in terms of effect on toxin production were 
reported by Sánchez-Hurtado (2007). However, this study reported different data in 
respect of PaLoc gene transcription. In the presence of amoxicillin tcdA, tcdR and 
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tcdE expression was up-regulated while that of tcdB was unaffected. Vancomycin 
showed no effects on transcription while clindamycin increased expression of all 
PaLoc genes. Metronidazole was shown to down-regulate tcdC. It should be noted 
that these data, unlike those of Gerber et al., refer to a single time point and that 
changes of expression may have occurred at time points other than that analysed. 
 
It is not possible to extrapolate from these in vitro findings to the situation in vivo, 
however, the use of a three-stage human gut model has attempted to address this. 
Freeman et al., (2007) showed that sub-MIC levels of metronidazole increase toxin 
titres. In a study examining the effects in the gut model of cefotaxime and its active 
metabolite desacetylcefotaxime it was shown that C. difficile remained in a steady 
state during non-antibiotic exposed periods, with no detectable cytotoxin. However, 
exposure to both antibiotics induced proliferation of C. difficile and elevated 
cytotoxin levels (Freeman et al., 2003). Conversely, the use of tigecycline was 
shown not to induce proliferation or cytotoxin production (Baines et al., 2006).  
 
1.8.9 Other virulence factors 
Binary toxin 
A strain of C. difficile that produced a third toxin, known as the binary toxin, was 
isolated by Popoff et al., in 1988. This binary toxin (CDT), an actin-specific ADP-
ribosyltransferase, has similar characteristics to the binary toxins of other clostridia 
and is unrelated to TcdA and TcdB. It does not produce the cytopathic effect 
typically induced by TcdA and TcdB. CDT consists of two subunits: CDTa and 
CDTb. CDTa is the enzymatic subunit that ADP-ribosylates monomeric actin, 
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resulting in cytoskeletal disruption. CDTb is the binding subunit responsible for the 
translocation of the enzymatic subunit into the cytoplasm (Barth et al., 2004). 
 
The prevalence of the binary toxin genes is relatively low. A European prospective 
study reported that 17.2% of toxigenic strains carried the binary toxin genes; all these 
strains were of variant toxinotypes (Barbut et al., 2007b). The role of binary toxin in 
the pathogenesis of CDI is not understood. While it is clearly not key to the 
development of disease, it has been suggested that it contributes to its severity. 
Barbut et al., (2007a) reported that binary toxin-positive strains, of varying ribotypes, 
were associated with more severe diarrhoea and with a higher case-fatality rate. 
Analysis of a collection of clinical samples by Geric et al., (2003) identified A-B- 
strains carrying the binary toxin genes that had been isolated from patients with 
diarrhoea. They could not, however, determine whether the strains had been the 
cause of the diarrhoea. Binary toxin preparations have been shown to induce fluid 
accumulation in the rabbit ileal loop model (Geric et al., 2006). However, challenge 
with A-B- CDT+ strains in a hamster model produced colonisation but no evidence of 
disease (Geric et al., 2006). It was posited that binary toxin alone does not cause 
disease but may act as an adjunct to TcdA and TcdB in pathogenesis.  
 
Surface proteins 
Borriello et al., (1987) hypothesised that adherence to the gut mucosa was an 
important contributor to the virulence of C. difficile. A number of cell-surface 
proteins have been identified as adhesins.  
The S-layer is a protective surface that contributes to the maintenance of envelope 
rigidity and shape of certain bacterial cells. In C. difficile the S-layer is comprised of 
 35 
two subunits, derived from a common precursor encoded by the slpA gene (Calabi et 
al., 2001). These S-layer proteins have been shown to adhere to gut epithelial cells 
(Calabi et al., 2002).   
 
Other surface proteins identified as putative adhesins include Cwp66, GroEL, Fbp68 
and FliD (Calabi et al., 2002; Cerquetti et al., 2000; Hennequin et al., 2001b, 2003; 
Karjalainen et al., 2001; Waligora et al., 2001). Cwp66 (“clostridial wall protein 66 
KDa”) is a surface heat-shock protein with a two domain structure (Waligora et al., 
2001). Its homology to known proteins indicates that its N-terminal domain is likely 
to be involved in adhesion.  GroEL (Hsp60) is another heat-shock protein, the 
expression of which is up-regulated in response to stressors such as heat, lack of iron, 
acid, high osmolarity and antibiotics (Hennequin et al., 2001a). Fbp68 is a 
fibronectin-binding protein, binding both soluble and immobilised fibronectin 
(Hennequin et al., 2003). Tasteyre et al., (2001) showed that FliD, the flagellar cap 
protein, adhered to mucus, an important first step in gut colonisation.  
 
Exposure to sub-MIC concentrations of ampicillin and clindamycin have been shown 
to moderately up-regulate expression of Cwp66, Fbp68 and S-layer proteins (Denève 
et al., 2008). Overexpression was correlated with increased adherence of C. difficile 
to cultured cells under the same conditions.  
Sánchez-Hurtado & Poxton (2008) investigated a possible modulating effect of cell-
surface antigens on the activity of C. difficile toxin A on Vero and Caco2 cells. They 
found that in the presence of an EDTA extract containing several major and minor 
cell-surface proteins and the membrane-associated lipocarbohydrate (LC) or a 
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preparation of free LC the cytotoxicity of suboptimal levels of toxin A was 
significantly enhanced in both cell types.  
 
C. difficile has a polysaccharide capsule that may be involved in adhesion and could 
contribute to evasion of the host immune system through its anti-phagocytic 
properties (Davies & Borriello, 1990). Complement components and antibodies do 
not bind as efficiently to encapsulated organisms, impairing the phagocytes’ ability 
to engulf the bacterial cell and protecting against complement-mediated lysis. In 
certain organisms the capsule mimics the composition of human tissue; for example 
the capsule of Streptococcus pyogenes is composed of hyaluronic acid, a polymer 
present in human connective tissue. The capsule thus prevents recognition of the 
organism by the host immune system.  
 
1.9 Immune response 
1.9.1 The immune system of the gut 
The intestine encounters more microbial antigen than any other part of the body; in 
addition to the commensal flora of the gut many pathogenic bacteria, viruses and 
parasites enter the body through the intestinal mucosa. The immune system of the gut 
has evolved to maintain the number and composition of commensal organisms while 
ensuring they remain within the gut lumen. Furthermore it acts to neutralise 
pathogens and maintains the integrity of the gut epithelium by minimising 
inflammatory tissue damage (Holmgren & Czerkinsky, 2005). This immune 
protection is provided by the gut-associated lymphoid tissues (GALT). GALT 
comprise the Peyer’s patches of the small intestine, the mesenteric lymph nodes and 
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the isolated lymphoid follicles of the large intestine. These tissues provide the site of 
induction of the adaptive immune response. The effector cells generated here are 
found throughout the epithelium and lamina propria of both the small and large 
intestine (Platt & Mowat, 2008).  A key feature of the mucosal immune system is the 
production of large quantities of IgA. Dimers of IgA are secreted into the gut lumen 
through the interaction with the polymeric Ig receptor expressed on the basolateral 
surface of epithelial cells (Mostov & Deitcher, 1986). Secretory IgA (SIga) inhibits 
bacterial adhesion, neutralises viruses and bacterial toxins and helps eliminate 
antigen from tissue by transporting it back into the lumen and promoting its uptake 
by phagocytic cells (Holmgren & Czerkinsky, 2005). Importantly, it also promotes 
the maintenance of commensal bacterial populations (Fagarasan et al., 2002).  
 
The presence of microbes is detected by cells of the innate immune system, including 
dendritic cells (DCs), macrophages and monocytes, through Toll-like receptors 
(TLRs). Individual TLRs recognise distinct pathogen-associated molecular patterns 
(PAMPs) that have been evolutionarily conserved in specific classes of microbes. 
Binding of these PAMPs to TLRs initiates events that usually result in the increased 
expression of pro-inflammatory genes (Cook et al., 2004). The anti-inflammatory 
milieu of the gut is maintained by a phenotypically distinct population of immune 
cells. Mucosal antigen-presenting DCs have been shown to be conditioned by 
epithelial cells to initiate polarised TH2 helper cell responses, characterised by the 
secretion of anti-inflammatory cytokines including IL-10, IL-4 and TGF-β (Rimoldi 
et al., 2005). These cytokines promote IgA class switching and production by 
activated B cells (Cerutti & Rescigno, 2008). DCs may also activate B cells to 
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produce IgA in a T cell-independent manner through the production of a B cell-
activating factor of the TNF family (BAFF) and a proliferation-inducing ligand 
(APRIL) (He et al., 2007). Recognition of PAMPs by TLRs present on DCs and 
intestinal epithelial cells stimulates production of BAFF and APRIL by both cell 
types (He et al., 2007). Intestinal macrophages differ from their peripheral 
counterparts in a number of ways. For instance, while they are highly phagocytic 
they fail to produce pro-inflammatory cytokines after the recognition of PAMPs by 
TLRs. It has been shown that this results from low expression of TLRs (Hausmann et 
al., 2002). Thus a major role of the intestinal macrophages is to maintain 
homeostasis. Protection against pathogens through the induction of an inflammatory 
response appears to be provided by the recruitment of a population of monocytes 
expressing a full range of TLRs (Platt & Mowat, 2008).  
 
1.9.2 The inflammatory response to CDI 
 
Colitis in CDI is characterised by a massive influx of neutrophils into the colonic 
mucosa and the pseudomembranes of PMC contain abundant dead neutrophils. IL-1, 
IL-8, TNF-α and leucotriene B4, produced by mucosal immune and epithelial cells, 
recruit neutrophils from the circulation to the site of inflammation (Souza et al., 
1997). In vitro, cultured monocytes can be stimulated to release TNF-α by both toxin 
A and toxin B (Souza et al., 1997). In vitro exposure to toxigenic C. difficile or to 
supernatants from toxigenic strains stimulates IL-8 production by intestinal epithelial 
cells (Canny et al., 2006).  Both toxins also activate monocytes and macrophages in 
the lamina propria in vitro to release IL-8 (Linevsky et al., 1997).  
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1.9.3 Host immune response to C. difficile 
 
It has been suggested that the differing clinical presentation of CDI reflects host 
rather than bacterial factors. A number of studies have addressed host immune 
response to C. difficile. 
 
Humoral response in initial episodes of CDI  
Kyne et al., (2000) performed a prospective study of the humoral response of 
patients colonised by C. difficile while hospitalised. Of the 47 patients identified 19 
remained asymptomatic.  Kyne et al., showed that asymptomatic carriage was 
associated with an effective anamnestic response to toxin A in which high levels of 
serum anti-toxin A IgG developed rapidly after colonisation. Conversely, those 
colonised patients with low levels of serum anti-toxin A IgG had a much greater risk 
of developing symptomatic disease. The levels of serum IgM against non-toxin 
antigens (products of sonication of non-toxigenic strains) were also found to be 
significantly higher in asymptomatic individuals. Levels of serum anti-toxin B IgG 
and anti-toxins IgM and IgA were not significantly different between the two groups. 
Furthermore, Kyne et al., identified the presence of severe underlying disease on 
admission as a risk factor for symptomatic disease. Colonised patients with severe or 
extremely severe underlying disease were eight times more likely to develop 
diarrhoea than those with less severe underlying disease. All colonised patients with 
high serum anti-toxin A IgG and less severe underlying disease were asymptomatic 




Péchiné et al., (2005) compared serum antibody levels in cases and controls to the 
adhesins Cwp66-Nterminal, Cwp66-Cterminal, FliC, FliD, Fbp68 and toxins A and 
B. They found that controls had a significantly higher level of antibodies to Cwp66-
Nterminal, FliC, FliD and Fbp68 than did cases: antibody levels to toxins A and B 
did not differ significantly. Drudy et al., (2004) analysed serum antibody levels to 
surface layer proteins in a population of hospitalised patients divided into case, 
carrier and control groups. No significant differences were found in levels of anti-
SLP IgG, IgM or IgA.  A study by Sánchez-Hurtado et al., (2008) compared the 
antibody response to colonisation in confirmed cases of CDI, asymptomatic carriers 
and non-colonised asymptomatic controls. Levels of IgG to antigens other than 
lipocarbohydrate were highest in cases and lowest in controls. Antibodies to 
lipocarbohydrate were higher in controls than cases.  Levels of antibodies in carriers 
were found to be similar to those in controls or of an intermediate level. The levels of 
IgM to all antigens were not significantly different among all three groups. The 
authors suggest that the immunological basis of predisposition to symptomatic 
disease may lie in the timing or specificity of the humoral immune response 
mounted.  
 
Humoral response in recurrent CDI 
Kyne et al., (2001) conducted a prospective study of a population with nosocomial 
CDI in which serum levels of IgG, IgA and IgM against toxins A and B and non-
toxin antigens were measured over a sixty-day period. Of the 44 participants 22 had 
recurrent diarrhoea. On day three of the first episode of diarrhoea patients who 
experienced a single episode had higher serum levels of anti-toxin A IgM than those 
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who experienced multiple episodes. On day 12 patients who had a single episode had 
higher serum levels of anti-toxin A IgG than those who experienced recurrent 
diarrhoea. The authors also reported that patients with recurrent diarrhoea were more 
likely to be older, have more severe underlying disease and to receive more 
antibiotics than patients experiencing a single episode. The odds ratio for recurrence 
associated with a low level of serum anti-toxin A IgG at 12 days post-onset of the 
initial episode of diarrhoea was 48.0 (95% CI 3.5-663) and the authors concluded 
that a serum antibody response to toxin A during the initial episode was protective 
against recurrence. Katchar et al., (2007) reported significantly lower levels of anti-
toxin A IgG2 and IgG3 subclasses in individuals with recurrent CDI.  
 
Drudy et al., (2004) examined the association between serum anti-SLP antibodies 
and recurrent diarrhoea and found that those patients experiencing multiple episodes 
had significantly lower levels of anti-SLP IgM than those experiencing a single 
episode.  
 
Mucosal cellular immune response 
Johal et al., (2004b) studied immune cell populations in colonic biopsies from 
controls with diarrhoea not caused by C. difficile and from patients with either mild 
or severe CDI. They found that T cell counts did not differ between the groups. 
There were, however, significant reductions in B/plasma cells and macrophage 
counts in CDI patients compared with controls. Analysis of the antibody class 
produced by B/plasma cells showed that there were significant reductions in IgA-
producing cells in biopsies from patients with CDI, with the greatest reduction being 
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seen in those from patients with PMC.  On the other hand, IgG-producing cells were 
seen to be significantly increased in biopsies from patients with CDI. Analysis of 
patients who relapsed revealed that only those with PMC did so and that biopsies 
from these patients gave significantly lower B/plasma cell and IgA-producing cell 
counts than biopsies from those patients with PMC who did not relapse.  
 
1.10 Fluoroquinolone resistance 
Bacterial resistance to fluoroquinolones is mediated by different mechanisms 
including mutations of DNA gyrase (the subunits of which are encoded by gyrA and 
gyrB) and topoisomerase IV genes (parC and parE), reduced permeability and the 
presence of efflux pumps (Higgins et al., 2003). Analysis of its genome has shown 
that C. difficile, in common with other organisms such as Treponema pallidum and 
Helicobacter pylori, lacks the genes for topoisomerase IV (Dridi et al., 2002). It has 
been suggested that the presence of mutations in both gyrA and parC in E. coli leads 
to higher levels of fluoroquinolone resistance (Bachoual et al., 2001), the implication 
being that lower levels of resistance may therefore be seen in C. difficile.  
 
Fluoroquinolone resistant isolates of C. difficile characterised to date have shown 
amino acid changes in the quinolone resistance determining region (QRDR) of GyrA 
and GyrB. GyrB changes are less common than GyrA and tend to confer low levels 
of resistance (Spigaglia et al., 2008). The GyrA amino acid substitution Thr82→ Ile 
has been reported by a number of groups (Ackermann et al., 2001; Dridi et al., 2002; 
Drudy et al., 2007; Schmidt et al., 2007; Spigaglia et al., 2008). This substitution has 
been demonstrated in all ribotype 027 strains characterised so far (Drudy et al., 2007; 
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Spigaglia et al., 2008). The presence of this substitution was associated with a high 
level of resistance to all fluoroquinolones tested by Spigaglia et al., (2008). Thr82 
corresponds to Ser83 in E. coli, the substitution of which alters the structure of the 
quinolone binding site near the interface of the enzyme and DNA (Hooper, 1999). 
Less frequently detected GyrA substitutions include Asp71→Val, Ala118→Thr 
(Dridi et al., 2002) and Thr82→Val (Ackermann et al., 2001). Drudy et al., (2006) 
reported the presence of the GyrB substitution Asp426→Val in a cluster of 5 clonal 
toxin-A-negative, toxin-B-positive outbreak isolates found to be resistant to five 
fluoroquinolones. Asp426 is thought to be a key site in GyrB; mutations in the 
corresponding codon in E. coli, Staphylococcus aureus and Streptococcus 
pneumoniae are associated with fluoroquinolone resistance (Hooper, 1999). No 
substitutions in GyrB have been noted to date in ribotype 027 strains (Drudy et al., 
2007; Spigaglia et al., 2008). 
 
Efflux pumps are known to be present in many bacteria. They can confer resistance 
to a variety of molecules, including antibiotics, by extrusion (Lebel et al., 2004). 
Little is known as yet about the role of efflux pumps in multidrug resistance in C. 
difficile. Dridi et al., (2004) cloned a gene designated cdeA (C. difficile efflux) under 
the control of its natural promoter into E. coli and Clostridium perfringens. It 
rendered the host cell resistant to ethidium bromide and acriflavin but not to a 
number of antibiotics including the fluoroquinolones norfloxacin and ciprofloxacin. 
However, when cloned and overexpressed under the control of the strong Plac 
promoter it conferred fluoroquinolone resistance on E. coli. BLAST analysis 
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revealed that the CdeA protein sequence was homologous to those of members of the 
MATE (multidrug and toxic compound extrusion) family of efflux pumps.  
 
Lebel et al., (2004) studied a second putative efflux gene designated cme 
(Clostridium multidrug efflux), homologous to members of the major facilitator 
superfamily such as NorA from Staph. aureus, Bmr from Bacillus subtilis and PmrA 
from Strep. pneumoniae. The cme gene conferred resistance to ethidium bromide, 
safranin O and erythromycin, but not norfloxacin, when cloned into Enterococcus 
faecalis. Susceptibility to these compounds was increased in the presence of 
reserpine, a selective inhibitor of proton motive force-driven efflux pumps.  
 
Immediately upstream of the cme gene in the C. difficile genome is a gene designated 
CD3197, a putative MerR family transcriptional regulator. Members of this family 
have been shown to activate suboptimal sigma 70-dependent promoters in which the 
-35 and -10 elements are separated by more than the optimal 17+/-1 bp (Brown et al., 
2003). Transcription is activated through protein-mediated DNA distortion and the 
majority of MerR regulators respond to environmental stressors such as the presence 
of antibiotics.  
 
1.11 Aims of the thesis 
This thesis consists of three studies: 
 
1.    A comparative study of immune cell populations within the lamina propria of 
colonic tissue taken from individuals either attending a colorectal surgery 
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outpatients’ clinic or undergoing elective colorectal surgery at the Western General, 
a large Acute hospital in Edinburgh. The study participants were divided into three 
groups on the basis of C. difficile colonisation status: cases (symptomatically 
colonised); carriers (asymptomatically colonised) and controls (asymptomatic and 
not colonised).  
 
The aim of this study was to quantify and compare effector T cells, B cells, plasma 
cells and macrophages within colonic tissue not exhibiting pathological changes 
taken from cases, carriers and controls. Previous research (Johal et al., 2004) 
reported significantly decreased numbers of IgA-secreting B/plasma cells and 
macrophages in cases compared with controls. Cases also showed significantly 
greater numbers of IgG-secreting cells. The study performed by Johal et al., reported 
findings from 12 controls and 16 cases, this population being of sufficient size to 
detect statistically significant differences. In the present study findings from six 
controls, six carriers and seven cases are reported. While this study is therefore 
underpowered the findings may still prove of use if incorporated into a metanalysis.  
The hypothesis for the present study was that comparable immune cell counts would 
be seen in carriers and controls, with both being higher than those seen in cases.  
 
2.  A number of studies have highlighted an association between the presence of 
certain host polymorphisms in genes associated with immune response and 
susceptibility to a variety of infections and diseases.  This study focused on 
polymorphisms identified in the TLR2, TLR5 and IL-8 genes.  
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TLR2 has been shown to be important in host defence against Gram-positive 
organisms. A polymorphism in the human TLR2 gene (Arg753Gln) is associated 
with a reduced response to bacterial lipoproteins and increased susceptibility to 
staphylococcal infection and tuberculosis.  TLR5 detects flagellin, the major protein 
constituent of flagella. Approximately 10% of Caucasian individuals carry a single 
nucleotide polymorphism (SNP) (TLR5392STOP) that is associated with a susceptibility 
to Legionnaires’ disease. IL-8 is a potent chemoattractant for neutrophils. Recent 
studies have demonstrated that a SNP (-251 A/A genotype) in the IL-8 promoter 
region is associated with increased susceptibility to CDI and with increased faecal 
IL-8 concentrations. The aim of this study was to establish the prevalence of these 
TLR2, TLR5 and IL-8 SNPs within this same study population and to determine 
whether an association existed between these genotypes and susceptibility to CDI.  
 
3. A recent study conducted by our group characterised clinical isolates in the 
Edinburgh area and found that 87% were resistant to moxifloxacin. The first aim of 
this study was to examine the mechanisms of fluoroquinolone resistance in this 
collection of isolates. It was hypothesised that the competitive advantage conferred 
by resistance to moxifloxacin may influence the fitness of C. difficile isolates, in 
particular growth and the expression of the virulence factors toxins A and B. Thus 
the second aim of this study was to determine whether a correlation exists between 
fitness and resistance or sensitivity to moxifloxacin.   
Taken as a whole these three studies examine factors pertaining to both the host and 
the organism that may influence the outcome of infection of an individual by C. 
difficile.  
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2. Materials and Methods 
 
2.1 Allocation of study participants to study groups 
 
Study participants were recruited from amongst the population of colorectal patients 
attending a surgical outpatients’ clinic or undergoing colorectal surgery at the 
Western General, a large Acute Edinburgh hospital. Participants were consented by 
Dr Surekha Reddy and each was allocated a sequential identification number of the 
form AW1. This number was used to identify tissue samples and faecal isolates 
where applicable. Participants were divided into three groups:  
Cases – those individuals with clinically diagnosed CDI (toxin A/B positive stools 
and/or positive for PMC on colonoscopy);  
Carriers - those individuals who were culture positive (toxin A/B variable) but 
asymptomatic;  
Controls - those individuals who were culture-negative (toxin A/B negative) and 
asymptomatic. It should be noted that while these individuals do not have CDI they 
are attending the colorectal unit and are therefore not “healthy” controls. 
 
2.1.1 Collection of faecal samples 
 
Faecal samples were collected during clinic appointments or after admission to 
hospital and prior to surgery, in accordance with the terms of the consent given by 
the Local Research Ethics Committee.  
 
2.1.2 Detection of toxin in stool samples 
 
A commercial ELISA kit for the detection of toxins A and B (TechLab) was used to 
perform toxin assays on fresh stool samples (within 24 hours of collection) in 
accordance with the manufacturer’s protocol.  
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2.1.3 Culture of stool samples and identification of C. difficile 
 
Stools were cultured on Brazier’s CCEY agar (Oxoid) and incubated at 37
o
C in 
anaerobic conditions (10% H2, 10% CO2 and 80% N2) for 24 to 48 hours. If no C. 
difficile colonies were seen within this period plates were incubated for a further 48 
hours to confirm that the samples were culture-negative. 
Preliminary identification of C. difficile was made on the basis of characteristic 
smell, colony morphology and visualisation of motility in a wet film observed by 
light microscopy. Examination of colonies under long wave UV light (Wood’s 
Lamp) to check for characteristic chartreuse fluorescence was also performed. If 
further confirmation was required a Gram stain and PCR amplification of a fragment 
of the cdd-3 gene, present in both toxigenic and non-toxigenic isolates, were 
performed. Isolates were stored on the bench at room temperature in cooked meat 
broth with cooked meat particles (Brown et al., 1996). 
 
2.2 Characterisation of faecal isolates 
2.2.1 Detection of toxin production in vitro 
If C. difficile was isolated from toxin-negative stools, the ability of the isolate to 
produce toxin was tested by growing it up in PPY (proteose peptone yeast medium) 
at 37
o
C under anaerobic conditions for 48 hours. PPY comprises 20g/L proteose 
peptone (Oxoid, Basingstoke, UK), 5g/L yeast extract (Oxoid, Basingstoke, UK), 
5g/L trypticase (Becton, Dickson & Company, Sparks, MD), 5g/L NaCl, 0.75g/L L-
cysteine-HCl, 0.4g/L Na2CO3, adjusted to pH 7.1. The presence of toxin in the 
growth medium was detected using an ELISA kit as previously described.  
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2.2.2 DNA extraction 
Genomic DNA was extracted from cultures following the method of de Lamballerie 
et al., (1992). Briefly, microbial cells, obtained by spinning down broth cultures or 
picking colonies from plates, were suspended in a 5% suspension of Chelex-100, a 
chelating resin (Bio-Rad Laboratories) and placed in a boiling bath. Following 





Ribotyping was performed using the method described by O’Neill et al., (1996). 
Specific oligonucleotide primers (obtained from MWG) complementary to the 3’ end 
of the 16s rRNA gene (positions 1445-1466) and the 5’ end of the 23s rRNA gene 
(positions 1-20) were used to amplify the intergenic spacer region which has been 
shown to be very heterogeneous. Primer sequences are given in Appendix 1.  
 
Amplification was performed in a 100µl reaction mixture containing 1x PCR buffer 
(10mM Tris HCl; 50mM KCl, Promega); 2.25mM MgCl2 (Promega); 200µM each 
dNTP (Amersham Pharmacia Biotech); 50pmol each primer; 2U of Taq (Promega) 
and 10µl of DNA template or, in the case of the negative control, sterile water. 
Cycling conditions were as follows: initial denaturation at 94°C for 4 minutes 
followed by 35 cycles of denaturation at 94°C for one minute; annealing at 55°C for 
one minute and extension at 72°C for one minute, with a final elongation step of 
72°C for five minutes. The amplification products were concentrated by heating at 
75°C for 100 minutes to obtain a final volume of 15µl and then run in a 3% 
Metaphor agarose gel (ABgene) for two and a half hours at 80 volts.  Ribotypes were 
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determined by comparing the banding patterns obtained with those held on the 
laboratory database.  
 
2.2.4 Toxinotyping  
Toxinotyping was performed using the method described by Rupnik et al., (1997, 
1998). Fragments of the tcdA (A3) and tcdB (B1) genes were amplified by PCR and 
digested with restriction enzymes. The resulting restriction pattern allows 
determination of the toxinotype of an isolate. The primers used were obtained from 
VHBio and their sequences are given in Appendix 1.  Amplification was performed 
in a 50µl reaction mixture containing 1x PCR buffer (10mM Tris-HCl; 50mM KCl, 
Promega); 3mM MgCl2 (Promega); 200µM each dNTP (Amersham Pharmacia 
Biotech); 15pmol each primer; 1U of Taq (Promega) and 5µl of DNA template or, in 
the case of the negative control, sterile water. The reaction mixture for the 
amplification of the A3 fragment also contained TMA (tetramethylammonium 
chloride, Sigma) with a final concentration of 10
-3
M. Cycling conditions were as 
follows; initial denaturation at 93°C for three minutes followed by 30 cycles for B1 
and 35 cycles for A3 of annealing and extension at 47°C for eight minutes and 
denaturation at 93°C for four seconds, with a final extension step at 47°C for 10 
minutes.  After visualisation of the fragments in 1% agarose gel, they were restricted 
using the enzymes EcoRI for A3 and HincII and AccI for B1 (enzymes were obtained 
from New England BioLabs). Restriction was performed in a 20µl digest volume 
containing 1µl of the appropriate enzyme and, in the case of HincII restriction of B1, 
10% BSA (Promega). Digest mixtures were incubated for two hours at 37°C and the 
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resulting fragments visualised in 1% agarose gel. The toxinotype of each isolate was 
determined as described by Rupnik et al., (1997, 1998).  
 
2.2.5 Detection of binary toxin genes 
The presence of the binary toxin genes was detected following the method of Stubbs 
et al., (2000). PCR primers were obtained from VHBio; their sequences are given in 
Appendix 1. Amplification was performed in a 50µl reaction mixture containing 1x 
PCR buffer (10mM Tris-HCl; 50mM KCl, Promega); 1.5mM MgCl2 (Promega); 
200µM each dNTP (Amersham Pharmacia Biotech); 10pmol each primer; 1U of Taq 
(Promega) and 5µl of DNA template or, in the case of the negative control, sterile 
water. Cycling conditions were as follows; 30 cycles of denaturation at 94°C for 45 
seconds, annealing at 52°C for one minute and extension at 72°C for one minute 20 
seconds. Products were visualised in 1% agarose gel. 
 
2.2.6 Amplification of cdd-3 gene 
PCR amplification was performed following the method of Cohen et al., (2000b); 
primer sequences are given in Appendix 1. Amplification was performed in a 50µl 
reaction mixture containing 1x PCR buffer (10mM Tris-HCl; 50mM KCl, Promega); 
2.5mM MgCl2 (Promega); 200µM each dNTP (Amersham Pharmacia Biotech); 
10pmol each primer; 1U of Taq (Promega) and 5µl of DNA template or, in the case 
of the negative control, sterile water. Cycling conditions were as follows; 40 cycles 
of denaturation at 95°C for one minute, annealing at 52°C for one minute and 
extension at 72°C for one minute, with a final extension step at 72°C for 10 minutes. 
Products were visualised in 1% agarose gel. 
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2.3 Analysis of tissue specimens 
2.3.1 Immunohistochemistry 
Colonic tissue specimens exhibiting no pathological changes, taken by biopsy or 
resection in the course of diagnosis or treatment, were obtained. The specimens had 
been fixed in formalin and embedded in paraffin wax.  
Cut and mounted sections were dewaxed in xylene and rehydrated by passage 
through graded alcohols and water. Antigen retrieval was performed by treatment of 
sections in Tris/EDTA (pH 9) in a pressure cooker for five minutes. Sections were 
cooled in water for 20 minutes before two washes in PBS, each of five minutes. 
Sections were then treated in 3% hydrogen peroxide for 10 minutes before a further 
two five minute washes in PBS. Unless otherwise stated subsequent steps were 
performed using reagents provided in a Vectastain Universal elite ABC peroxidase 
kit (Vector Laboratories Inc, Burlingame, California, USA) in accordance with the 
manufacturer’s instructions. Sections were blocked using a Vector Avidin/Biotin 
blocking kit (Vector Laboratories Inc), each reagent being applied for 15 minutes and 
sections rinsed between steps. After a five minute wash in PBS sections were 
blocked with normal horse serum for 10 minutes. Sections were subsequently 
incubated with 100µl of primary antibody, diluted in PBS, for one hour at room 
temperature. A negative control section was incubated with PBS in place of 
antibody. The primary antibodies used were specific for T cells (monoclonal mouse 
anti-CD3; Dako, Ely, Cambridgeshire, UK), B cells (monoclonal mouse anti-CD20; 
Dako), plasma cells (mouse anti-CD138; Serotec, Kidlington, Oxfordshire, UK) and 
macrophages (monoclonal mouse anti-CD68; Dako). Primary antibodies to CD3, 
CD20 and CD68 were diluted 1 in 500, while those to CD138 were diluted 1 in 1000. 
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After washing in PBS for five minutes sections were incubated with diluted 
biotinylated secondary antibody for 30 minutes. After a further five minute wash in 
PBS sections were incubated with Vectastain reagent for 30 minutes, then washed in 
PBS for five minutes. Labelled cells were visualised using DAB (Vector 
Laboratories Inc), the sections being incubated for 2-10 minutes at room temperature 
until suitable staining developed. After washing in water for five minutes sections 
were counterstained in haematoxylin, washed in water and dehydrated by passage 
through graded alcohols and xylene. Coverslips were attached and the slides allowed 
to dry before viewing. Counts of positively labelled cells within the lamina propria 
were carried out using a light microscope fitted with a stage and a 10 x 10 grid 
graticule in the eyepiece. Ten fields were examined for each slide and the mean 
count for each section calculated.  
 
2.4 Analysis of single nucleotide polymorphisms 
 
2.4.1 Extraction of genomic DNA from tissue sections 
 
 
DNA was extracted from fixed, paraffin wax-embedded tissue sections using the 
method outlined by Coombs et al., (1999). A 20 µm section was cut and placed in an 
Eppendorf tube. The tissue was deparaffinised by adding 100 µl of 0.5% Tween-20, 
agitating and heating to 90°C for 10 minutes on a Techne Thermal Cycler. Sections 
were then cooled to 55°C, the wax remaining in solution prior to digestion. This was 
performed by the addition of 2 µl of 10 mg/ml Proteinase K (Sigma) to give a final 
concentration of 200 µg/ml, followed by digestion for three hours at 55°C. Each 
digest solution was then heated to 99°C for 10 minutes with 100 µl of 5% Chelex-
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100 suspended in Tris-EDTA. The solutions were gently shaken, centrifuged at 
10,500 g for 15 minutes whilst still hot and then placed on ice to allow the wax to 
harden and be removed. The samples were then heated to 45°C and 100µl of 
chloroform added. After gentle agitation and centrifugation at 10,500 g for 15 
minutes, the top phase was removed and stored at -20°C.  
 
2.4.2 Genotyping of the IL-8 -251 allele 
Genotyping was performed using a modification of the method described by Hull et 
al., (2000). Allele-specific primers were used to identify the presence of the IL-8  
-251 A and T alleles. Primers were obtained from VHBio and sequences are given in 
Appendix 1. Amplification was performed in a 50 µl reaction mixture containing 1x 
PCR buffer (10mM Tris-HCl; 50mM KCl, Promega); 1.5mM MgCl2 (Promega); 
200µM each dNTP (Amersham Pharmacia Biotech); 10pmol each primer; 1U of Taq 
(Promega) and 2.5µl of DNA template or, in the case of the negative control, sterile 
water. Cycling conditions were as follows; initial denaturation at 94°C for 10 
minutes followed by 35 cycles of denaturation at 94°C for one minute, annealing at 
55°C for one minute and extension at 72°C for one minute, with a final extension 
step at 72°C for 10 minutes. Products were visualised in 1% agarose gel.  
 
2.4.3 Genotyping of the TLR2 allele 
Genotyping was performed using the method described by Ogus et al., (2004). 
Allele-specific primers were used to identify the presence of the TLR2 2258 A and G 
alleles. Primers were obtained from VHBio and sequences are given in Appendix 1. 
Amplification was performed in a 50 µl reaction mixture containing 1x PCR buffer 
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(10mM Tris-HCl; 50mM KCl, Promega); 2mM MgCl2 (Promega); 200µM each 
dNTP (Amersham Pharmacia Biotech); 10pmol each primer; 1U of Taq (Promega) 
and 2µl of DNA template or, in the case of the negative control, sterile water. 
Cycling conditions were as follows; initial denaturation at 94°C for four minutes 
followed by 35 cycles of denaturation at 94°C for one minute, annealing at 62°C for 
one minute and extension at 72°C for one minute, with a final extension step at 72°C 
for four minutes. Products were visualised in 1% agarose gel.  
 
2.4.4 Genotyping of the TLR5 allele 
Genotyping was performed using the method described by Hawn et al., (2003). 
Primers were obtained from VHBio and sequences are given in Appendix 1. 
Amplification was performed in a 50 µl reaction mixture containing 1x PCR buffer 
(10mM Tris-HCl; 50mM KCl, Promega); 1.5mM MgCl2 (Promega); 200µM each 
dNTP (Amersham Pharmacia Biotech); 10pmol each primer; 1U of Taq (Promega) 
and 2µl of DNA template or, in the case of the negative control, sterile water. 
Cycling conditions were as follows; initial denaturation at 94°C for five minutes 
followed by 30 cycles of denaturation at 94°C for one minute, annealing at 55°C for 
one minute and extension at 72°C for one minute, with a final extension step at 72°C 
for five minutes. The products of amplification were subjected to digestion with the 
DdeI restriction enzyme. Digestion was performed in a 20µl reaction mixture 
containing 1x enzyme buffer (Promega); 0.02µg BSA; 1µl of restriction enzyme 
(Promega) and 10µl of PCR product. Digest mixtures were incubated at 37°C for two 
hours and products were visualised in 1.8% agarose gel. The restriction enzyme cuts 
the variant allele only.  
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2.5 Moxifloxacin resistance and virulence factors 
2.5.1 Isolates  
Fourteen moxifloxacin-resistant and 14 sensitive isolates, as shown in Table 2.1, 
were selected from a collection of organisms isolated from toxin-positive stools 
collected between August and October 2005 from different hospitals in the 
Edinburgh area (Lothian University Hospitals National Health Service Trust). This 
collection has been previously characterised by Mutlu et al., (2007). 
 
Strain Ribotype MIC moxifloxacin (µg ml-1) 
EM23 001 32 
EM24 001 16 
EM27 001 16 
EM28 001 16 
EM30 001 32 
EM31 001 32 
EM47 070 8 
EM57 106 32 
EM58 106 32 
EM64 106 32 
EM82 106 64 
EM125 106 16 
EM184 001 16 
EM186 001 16 
EM5 023 2.5 
EM14 014 2 
EM36 042 2 
EM83 002 1.5 
EM84 070 2.5 
EM87 005 1.5 
EM96 005 1.5 
EM102 001 1 
EM109 049 1.5 
EM120 002 2 
EM126 005 1 
EM130 106 1.5 
EM169 020 2 
EM185 013 0.25 
 





2.5.2 Culture of organisms and determination of growth  
The isolates were grown from spores preserved in cooked meat broth with cooked 
meat particles (Brown et al., 1996). To prepare the starter culture, 0.5ml of the spore 
suspension was added to 3ml of pre-reduced PPY and incubated anaerobically 
overnight at 37
o
C. The starter culture (2ml) was inoculated in 200ml of pre-reduced 
PPY. Ten ml of the cultures were taken every four hours for the first 16 hours, then 
at 24, 36 and 48 hours. Total cell counts at each time point were measured by taking 
aliquots of culture medium and measuring optical density (OD) at 600nm by 
spectrophotometer.  
Cells were collected by centrifugation at 4,000 g for 20min, followed by 5 minutes at 
9,000 g for maximal removal of the medium. The pellets were snap frozen in an 
ethanol-ice mixture and stored at -20°C prior to RNA extraction. 
 
2.5.3 Toxin production 
The amount of toxin present in the growth medium at a particular time point was 
determined using a commercial ELISA kit as previously described.  
 
2.5.4 RNA extraction 
RNA was extracted from pellets using a RiboPure kit (Ambion) in accordance with 
the manufacturer’s protocol and its concentration estimated using the Nanodrop ND-
1000 Spectrophotometer (Labtech). The RNA was checked for genomic DNA 





2.5.5 Reverse transcription 
500ng of RNA were used as the template for cDNA synthesis using either a 
RetroScript (Ambion) or Superscript
®
 VILO™ (Invitrogen) kit in accordance with 
the manufacturer’s protocol, the products being stored at -20°C. 
 
2.5.6 Semi-quantitative detection of gene expression  
PCR primers were obtained from VHBio and sequences are shown in Appendix 1. A 
2µl volume of cDNA preparations or, in the case of the negative control, sterile water 
was used in all amplification reactions.  
 
Amplification of tcdA and tcdB 
Fragments of the toxin A and B genes, tcdA and tcdB, were amplified separately 
following the method of Spigaglia & Mastrantonio (2002). Amplification was 
performed in a 50µl reaction mixture containing 1x buffer (10mM Tris-HCl, 50mM 
KCl, Promega); 2.5mM MgCl2 (Promega); 200µM each dNTP (Amersham 
Pharmacia Biotech); 100pmol of TA1 and TA2 primers or 25 pmol TB1 and TB2 
primers and 2U of Taq (Promega). The template was denatured for 2 minutes at 95°C 
and then amplified for 30 cycles consisting of one minute at 95°C, one minute at 
50°C and one minute at 72°C, with a final extension of 10 minutes at 72°C. Products 
were visualised on 1% agarose gel. 
 
Amplification of cme 
The cme gene was amplified in a 50µl reaction mixture containing 1 x buffer (10mM 
Tris-HCl, 50mM KCl, Promega); 2.5mM MgCl2 (Promega); 200 µM each dNTP 
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(Amersham Pharmacia Biotech); 20pmol of forward and reverse primers and 1U of 
Taq (Promega). The template was denatured for three minutes at 95°C and then 
amplified for 30 cycles consisting of one minute at 95°C, one minute at 52°C and 
one minute at 72°C, with a final extension of 10 minutes at 72°C. Products were 
visualised in 1.5% agarose gel. 
 
Amplification of cdeA 
The cdeA gene was amplified following the method of Dridi et al., (2004). 
Amplification was performed in a 50µl reaction mixture containing 1 x buffer 
(10mM Tris-HCl, 50mM KCl, Promega); 1.5mM MgCl2 (Promega); 200pmol of 
each dNTP (Amersham Pharmacia Biotech); 20pmol of forward and reverse primers 
and 1U of Taq (Promega).  The template was denatured for two minutes at 94°C and 
then amplified for 30 cycles consisting of one minute at 94°C, one minute at 55°C 
and one minute at 72°C, with a final extension of five minutes at 72°C. Products 
were visualised in 1% agarose gel. 
 
Semi-quantitative RT-PCRs were normalised by comparison with the products of 
amplification of a region of the 16s rRNA gene, following the method of Nübel et 
al., (1996). The 16s rRNA gene is transcribed at high levels throughout the 
exponential and stationary phases of growth. For each experiment the same cDNA 
preparation was used as the template for analysis of both the gene of interest and 16s 
expression. Primers were obtained from VHBio and used to amplify the segment 
from nucleotide 986 to nucleotide 1041; sequences are given in Appendix 1. 
Amplification was performed in a 50 µl reaction mixture containing 1x PCR buffer 
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(10mM Tris-HCl; 50mM KCl, Promega); 2.5mM MgCl2 (Promega); 200µM each 
dNTP (Amersham Pharmacia Biotech); 10pmol each primer and 1U of Taq 
(Promega). Cycling conditions were as follows; initial denaturation at 94°C for five 
minutes followed by 22 cycles of denaturation at 94°C for one minute, annealing at 
63°C for one minute and extension at 72°C for one minute, with a final extension 
step at 72°C for five minutes. Products were visualised in 1.5% agarose gel.  
 
 2.5.7 Sequencing of the tcdC, gyrA, gyrB and CD3197 genes 
PCR primers were obtained from VHBio and sequences are shown in Appendix 1. A 
2µl volume of genomic DNA extracts (prepared as described above) was used in all 
amplification reactions.  
 
A 900bp fragment of the PaLoc encompassing the tcdC gene was amplified with 
primers tcdC-F and tcdC-R. Amplification was performed in a 50 µl reaction mixture 
containing 1x buffer (10mM Tris-HCl, 50mM KCl, Promega); 2.5mM MgCl2 
(Promega); 200µM each dNTP (Amersham Pharmacia Biotech); 10pmol of each 
primer and 2U of Taq (Promega). The template was denatured for two minutes at 
95°C and amplified for 30 cycles consisting of one minute at 95°C, one minute at 
52°C and one minute at 72°C, with a final extension of 10 minutes at 72°C. 
Automated Sanger sequencing was performed and fragment sequences were 
compared with the published sequence of the tcdC gene of reference strain VPI10463 
using MultAlin.  
The QRDR of the gyrA and gyrB genes was amplified separately with primers 
GyrAF and GyrAR and GyrBF and GyrBR respectively, following the method of 
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Drudy et al., (2006).  The 50µl reaction mixture contained 1x buffer (10mM Tris-
HCl, 50mM KCl, Promega); 2.5mM MgCl2 (Promega); 10nmol of each dNTP 
(Amersham Pharmacia Biotech); 10pmol of each primer and 1U of Taq (Promega). 
The template was denatured for three minutes at 95°C then amplified for 30 cycles 
consisting of one minute at 95°C, one minute at 46°C and one minute at 72°C. 
Sanger sequencing was performed and fragment sequences were compared with the 
published sequence of the gyrA and gyrB genes of reference strain 630 using 
MultAlin. 
The transcriptional regulatory region CD3197 was amplified in a 50µl reaction 
mixture containing 1 x buffer (10mM Tris-HCl, 50mM KCl, Promega); 1.5mM 
MgCl2 (Promega);  200µM each dNTP (Amersham Pharmacia Biotech); 20pmol of 
forward and reverse primers (MerR F and MerR R) and 1U of Taq (Promega). The 
template was denatured for two minutes at 94°C then amplified for 30 cycles 
consisting of one minute at 94°C, one minute at 55°C and one minute at 72°C. A 
final extension step of five minutes at 72°C was performed. The putative promoter 
region of CD3197 was amplified in a 50µl reaction mixture containing 1 x buffer 
(10mM Tris-HCl, 50mM KCl, Promega); 1.5mM MgCl2 (Promega);  200µM each 
dNTP (Amersham Pharmacia Biotech); 20pmol of forward and reverse primers 
(CD3197 F and CD3197 R) and 1U of Taq (Promega). The template was denatured 
for two minutes at 94°C then amplified for 30 cycles consisting of one minute at 
94°C, one minute at 55°C and one minute at 72°C. A final extension step of five 
minutes at 72°C was performed. Sanger sequencing was performed and fragment 
sequences were compared with the published sequence of the CD3197 region of 
reference strain 630 using MultAlin. 
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2.5.8 Analysis of amino acid sequence of GyrA, GyrB and CD3197 
The amino acid sequence was derived from the nucleotide sequence using the 
ExPASy web tool and compared with the published sequence of reference strain 630.  
 
2.5.9 Antibiotic susceptibility testing 
MICs were determined
 
using the agar dilution protocol given in the Clinical 
Laboratories Standards Institute guidelines (CLSI, 2001).
 
Concentrations of 
moxifloxacin (Bayer) used were 128 - 0.5µg ml
–1
. The isolates were subcultured 
from cooked meat broth into pre-reduced
 
thioglycollate medium (Sigma) enriched 
with 5 µg haemin,
 





in an anaerobic chamber at 37°C. After adjusting
 
the turbidity to 0.5 McFarland 
standard, aliquots (1–2
 
µl) of the cultures were spotted onto Brucella agar (Oxoid),
 
supplemented with haemin, vitamin K1 and 5% lysed horse blood
 
plus moxifloxacin 
of a given concentration, using a multipoint
 
inoculator and incubated anaerobically at 
37°C for 48 hours.
 
Control plates containing no antibiotic were also inoculated and 
incubated both anaerobically and aerobically
 
to check for aerobe contamination. 
Reference strain 630
 
was used as a control strain as its MIC was known from a 
previous study (Drummond et al., 2003a).  
2.5.10 Single passage mutants 
An overnight culture of the moxifloxacin-sensitive isolate EM96 (MIC 1.5 µg ml
-1
) 
was grown up in pre-reduced thioglycollate medium as described above. 100µl of 
neat culture were spread onto Brucella agar plates, prepared as described above, plus 
1.5 µg ml
-1
, 2 µg ml
-1 
or 3 µg ml
-1 
moxifloxacin.  The plates were checked after 24 
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and 48 hours and new colonies present at each time point were marked. After 48 
hours colonies were picked and subcultured to pre-reduced thioglycollate medium 
overnight prior to their MICs being determined as described above. The colony with 
the highest MIC was identified and further passaged on plates containing increasing 
concentrations of moxifloxacin. This process was repeated until a moxifloxacin 
mutant with reduced susceptibility was obtained. 
2.6 Statistics 
Statistical analysis was performed using the Minitab 15 package. Data were analysed 
by means of the Kruskal-Wallis one-way ANOVA, MANOVA and Mann-Whitney 
tests. P values of ≤ 0.05 were considered statistically significant. Given the small 
sample size for each study population no formal statistical analysis of the genotyping 










3. Study population and characterisation of C. 
difficile isolates 
3.1 Study population 
One hundred and fourteen individuals were recruited to the study, of whom 98 were 
recruited from among individuals attending the colorectal outpatient clinic or 
undergoing colorectal surgery at the Western General Hospital, Edinburgh. The 
remaining 16, also colorectal patients and either cases or carriers, were identified in one 
of three ways: clinically, on the basis of findings at colonoscopy; the submission of 
toxin-positive stools to the hospital’s microbiology diagnostic laboratory or through 
culture by Dr Reddy of faecal samples submitted to the diagnostic laboratory.  It is 
important to note that for a period of time stool samples from all patients on the 
colorectal surgery wards, whether symptomatic or not, were submitted for C. difficile 
testing and asymptomatic carriers were identified from these samples. 
 
Nine carriers were identified; three from the culture of diagnostic laboratory samples 
and six from the colorectal clinic population. These data indicate that the carriage rate 
among the general population is 6% (6/98); this accords with published data reporting 
carriage rates in healthy adults of 3 - 7% (Kato et al., 2001; Kelly & LaMont, 1998). 
Thirteen cases were identified, two from among the clinic population who developed 
CDI following admission for surgery and 11 through toxin-positive stool samples 
submitted to the diagnostic laboratory.  
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It was only possible to obtain colonic tissue samples for seven cases (including the two 
described above who were from the clinic population), six carriers and six controls, 
giving an experimental study population of 19. The mean ages of the groups were 83, 72 
and 70 respectively; there was no statistically significant difference in age between the 
groups (p=0.31). The cases group comprised six females and one male; the carriers 
group five females and one male and the control group four males and two females. 
Although the control group is not gender matched to the other groups this is not 
considered of concern as there is no evidence to suggest that an association exists 
between gender and susceptibility to CDI. 
 
3.2 Characterisation of isolates 
Twenty three isolates of C. difficile from 19 of the 22 cases and carriers were 
characterised (Table 3.1). No organisms were isolated from two cases, clinically 
diagnosed, and the cooked meat broth in which an isolate from a carrier was being 
stored was destroyed in error. Multiple stool samples were obtained from the hospital 
diagnostic laboratory for three individuals; two isolates each were isolated from two 
individuals and three from the third.  
 
Ribotypes 
Ribotypes were identified for 18 isolates; 17 were ribotype 001 (94.4%) and one 
ribotype 126. Ribotype 001 was the second most common in Scotland as a whole in the 
three months to December 2008 among isolates typed by the Scottish Reference 
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Laboratory (HPS C. difficile Working Group, 2009a), while a study by Mutlu et al., 
(2007) characterising clinical isolates collected in south-east Scotland in 2005 found 
ribotype 001 to be the most common (75.8%). All multiple isolates from individuals 
were found to be of the same ribotype.  
 
Toxinotypes 
Toxinotypes were identified for 22 isolates; 19 were of toxinotype 0 (86.4%) and three 
were variant toxinotypes, two being V and one being IV. The findings of Mutlu et al., 
(2007) are comparable; the majority of these isolates (96.6 %) were of toxinotype 0, 
with two toxinotype V isolates and single isolates of toxinotypes I, IV and XIII.  
 
Presence of binary toxin genes 
The binary toxin genes, cdtA and cdtB, were found in only two isolates, both variant 
toxinotype V. Again these findings correspond with those of Mutlu et al., (2007) who 
detected the binary toxin genes in three isolates: two isolates of toxinotype V and one 
isolate of toxinotype IV. There were no differences between the isolates obtained from 
carriers and cases in terms of ribotype or toxinotype.  
 
Toxin production by isolates 
In all bar one instance, a carrier, stools from which C. difficile was isolated were found 
to be positive for the presence of toxin A and/or B, as measured by ELISA. The 
organism isolated from this one individual was cultured in vitro and culture supernatant 
was tested for the presence of toxins; the isolate was seen to be toxigenic.  
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Strain Isolated from Ribotype Toxinotype cdtA/cdtB 
AW7 Carrier ND 0 N 
AW21 Carrier ND 0 N 
AW57 Carrier 1 0 N 
AW82 Carrier ND V Y 
AW88 Carrier 1 IV N 
AW106 Carrier 1 0 N 
AW107 Carrier 1 0 N 
AW108 Carrier 1 0 N 
AW89 Case 1 0 N 
AW95A Case 1 0 N 
AW95B Case 1 0 N 
AW96 Case ND 0 N 
AW97 Case ND 0 N 
AW98A Case 1 0 N 
AW98B Case 1 0 N 
AW98C Case 1 ND ND 
AW99A Case 1 0 N 
AW99B Case 1 0 N 
AW100 Case 1 0 N 
AW101 Case 126 V Y 
AW109 Case 1 0 N 
AW110 Case 1 0 N 
AW111 Case 1 0 N 
 
Table 3.1 Characterisation of isolates. ND indicates not determined. 
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The lymphoid elements of the large intestine comprise organised lymphoid tissue 
including mesenteric lymph nodes and isolated lymphoid follicles. These follicles 
contain a core of B cells surrounded by T cells and host the induction phase of the 
adaptive immune response (Platt & Mowat, 2008). The effector cells of the mucosal 
immune system are found in the epithelium and lamina propria and include activated T 
cells, B and plasma cells, dendritic cells, mast cells and macrophages.  
The aim of this study was to quantify and compare effector T cells, B cells, plasma cells 
and macrophages within the lamina propria of colonic tissue not exhibiting pathological 
changes taken from cases, carriers and controls. Previous research (Johal et al., 2004b) 
reported significantly decreased numbers of IgA-secreting B/plasma cells and 
macrophages in cases compared with controls. Cases also showed significantly greater 
numbers of IgG-secreting cells. The hypothesis for the present study was that 
comparable immune cell counts would be seen in carriers and controls, with both being 





4.2 Materials and methods 
Colonic tissue specimens, taken by biopsy or resection in the course of diagnosis or 
treatment, were obtained. The specimens, which were fixed in formalin and embedded in 
paraffin wax, were sectioned and mounted on slides. One section from each specimen 
was stained with haematoxylin and eosin and examined by Dr Paul Fineron to establish 
that the colonic tissue present did not exhibit pathological changes.  
Suitable specimens were obtained for six of the nine identified carriers and equivalent 
numbers of cases and controls were selected (seven cases and six controls). Sections of 
the specimens from these 19 individuals were incubated with cell-specific monoclonal 
antibodies and the cell populations were enumerated as described in section 2.3.1. It was 
intended that B and plasma cells would also be stained to show the class of 
immunoglobulin secreted. However, it proved difficult to optimise the protocol, 
particularly for IgA which having been secreted is found throughout tissue, thus this 
analysis was not pursued.  
 
4.3 Results 
Representative photographs of labelled tissue sections are shown below.  Figure 4.1 
shows CD3-labelled T cells, Figure 4.2 CD20-labelled B cells, Figure 4.3 CD68-labelled 
macrophages and Figure 4.4 CD138-labelled plasma cells. 
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Figure 4.1. CD3-labelled T cells in a tissue specimen taken from a control. To the left of the picture T 
cells can be seen around the perimeter of a lymphoid follicle (large arrow). Isolated T cells in the lamina 
propria can be seen in the areas between glands to the right (small arrows).  
 
 
Figure 4.2. CD20-labelled B cells in a tissue specimen taken from a case. A lymphoid follicle can be seen 










Figure 4.4. CD138-labelled plasma 
cells in a tissue specimen taken from a 
case. Epithelial cells of surrounding 




4.3.1 Immune cell counts 
Cell counts for each study participant and cell type are given in Table 4.1.  
 
Study Participant  Study Group Mean count per mm2 
  T cells B cells Plasma cells Macrophages 
AW96 Case 156 6 50 150 
AW97 Case 75 13 * * 
AW95 Case 75 6 6 56 
AW103 Case 156 19 25 219 
AW81 Case 122 29 94 119 
AW98 Case 56 19 125 94 
AW89 Case 94 25 138 169 
AW25 Control 244 25 169 356 
AW6 Control 138 44 300 250 
AW10 Control 63 6 56 169 
AW75 Control 125 56 294 31 
AW42 Control 131 13 206 213 
AW4 Control 94 25 69 138 
AW57 Carrier 6 0 19 56 
AW82 Carrier 100 19 69 138 
AW88 Carrier 188 38 38 200 
AW106 Carrier 106 6 50 81 
AW107 Carrier 56 6 44 63 
AW108 Carrier 69 6 94 69 
 
Table 4.1. Mean cell counts per square millimetre of colonic tissue. An asterisk indicates that a labelled 
section was not available for enumeration. 
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Analysis of macrophage counts 
Figure 4.5 compares median macrophage counts for cases, carriers and controls. There is 
no statistically significant difference between the three groups (p = 0.22). However, it 
can be seen that carriers have a lower median count than both cases and controls; these 
differences are not significant (p = 0.32 and 0.15 respectively). Cases have a lower 























Figure 4.5. Macrophage counts per mm
2 
of sectioned colonic tissue. Boxes represent the range between 
quartile 1 and quartile 3, with the median value represented by the horizontal line. The whiskers indicate 
highest and lowest values. 
 
 
Analysis of T cell counts 
Figure 4.6 compares median T cells counts for cases, carriers and controls. No 
statistically significant difference exists between the three groups (p = 0.49). Again it 
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can be seen that carriers have a lower median count than both cases and controls 
although these differences are not significant (p = 0.56 and 0.23 respectively). Cases 
























Figure 4.6. T cell counts per mm
2 
of sectioned colonic tissue. Boxes represent the range between quartile 
1 and quartile 3, with the median value represented by the horizontal line. The whiskers indicate highest 
and lowest values. 
 
 
Analysis of B cell counts 
Figure 4.7 compares median B cell counts for the three study groups; there is no 
statistically significant difference between them (p =0.16). Compared with the other cell 
types examined B cells are present in low numbers in all three groups, with the lowest 
median count being seen in the carriers. No significant difference in the median counts 
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exists between cases and carriers (p = 0.26) or carriers and controls (p = 0.14). While 

























Figure 4.7.  B cell counts per mm
2 
of sectioned colonic tissue. Boxes represent the range between quartile 
1 and quartile 3, with the median value represented by the horizontal line. The whiskers indicate highest 
and lowest values. 
 
 
Analysis of plasma cell counts 
Figure 4.8 compares median plasma cell counts for the study groups. The difference in 
the median counts between the three groups is statistically significant (p = 0.049). While 
carriers have a lower median count than cases this is not significant (p = 0.32) nor is the 
difference in counts between cases and controls (p = 0.13). However, the difference 

























Figure 4.8.  Plasma cell counts per mm
2 
of sectioned colonic tissue. Boxes represent the range between 
quartile 1 and quartile 3, with the median value represented by the horizontal line. The whiskers indicate 




Analysis of total cell counts 
A multivariate analysis using the four cell counts for each individual as the vector 
response variable and the three study groups as the explanatory variable yielded a p-
value of 0.168. Thus, this analysis provides no evidence overall for differences between 







The data derived from this pilot study support the findings of Johal et al., (2004b). Cases 
were found to have fewer of all cell types than controls although, unlike that study, these 
differences were not significant. However, the data do not support this study’s 
hypothesis; carriers were found to have fewer of all four cell types examined than both 
cases and controls, although in only one instance was this difference significant.  
These findings suggest that individuals who become infected, both symptomatically and 
asymptomatically, with C. difficile display altered mucosal immune cell populations 
when compared with those of uninfected individuals. With regard to cases it can be 
concluded that these differences pre-dated the development of symptomatic illness 
which occurred post-admission and resection or biopsy. However, while it is known that 
the two individuals from the clinic population were not infected at the time a faecal 
sample was taken pre-admission, the point at which they or the remaining cases became 
infected during admission cannot be determined. It is therefore not possible to conclude 
that the differences pre-dated infection. In the case of those carriers who were infected at 
the time faecal samples were taken at the outpatients’ clinic, and therefore prior to the 
taking of tissue specimens, it is also not possible to determine whether these differences 
in cell populations pre-dated infection. Furthermore, the point at which carriers 
identified from culture of diagnostic laboratory samples were infected is not known. 
Thus on the basis of the study performed here it cannot be determined if these changes 
represent a predisposition to infection or have arisen as a result of exposure to the 
organism. It has been demonstrated that exposure of isolated colonic lamina propria cells 
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to high levels of toxin A in vitro results in macrophage loss within 72 hours (Mahida et 
al., 1998). Exposure over longer periods of time resulted in apoptosis of T cells and 
eosinophils. Purified monocytes are also highly susceptible to toxin A-induced cell 
death, being lost much more rapidly than circulating B or T cells (Solomon et al., 2005). 
While toxin B has not been shown to induce cell death in monocytes and macrophages it 
does induce rearrangement of the cytoskeleton producing morphological and functional 
changes (Siffert et al., 1993).   
 
The data do, however, suggest that cases and carriers mount a different immune 
response in the face of infection.  In the case of carriers, even though the populations of 
effector cells are reduced, the response is protective against symptomatic infection. To 
understand the nature of this protective response it would be necessary to characterise 
the B and plasma cells in terms of the immunoglobulin class secreted and the antigen-
specificity of the antibodies produced. It could be hypothesised on the basis of the 
findings of Johal et al., (2004b) that even though cases have a greater number of plasma 
cells than do carriers, these are predominantly IgG-secreting, this class of 
immunoglobulin being less effective at protecting mucosal surfaces than IgA. The 
antibodies produced may also be specific for antigens that do not play a major part in 
pathogenesis. On the other hand, the plasma cells found in the lamina propria of carriers 
may be IgA-secreting and specific for C. difficile toxins and cell wall components such 
as the S-layer proteins and the adhesin Cwp66. Research into vaccine candidates has 
shown that immunisation of mice with a C. difficile cell wall extract containing these 
proteins protects against CDI, possibly by counteracting colonisation (Péchiné et al., 
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2007). Characterisation of the antigen-specificity of effector CD4
+ 
T cells, particularly 
the TH2 subtype, would also be required.  
In conclusion, statistical analysis of the small data set reported in this study indicates 
that no significant differences exist in mucosal immune cell counts between the three 
study groups, although cell counts are seen to be lower in cases and carriers than in 
controls. A larger, more detailed study of the mucosal immune response would be 
required to cast light on the role of the host in determining the outcome of infection. A 
prospective study in which a series of faecal and tissue specimens were taken prior to 
and during hospitalisation would be most informative.  
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5. Genetic polymorphisms  
 
 
5.1 Introduction  
 
As mentioned in section 1.9.1 TLRs are an integral part of microbial recognition by the 
innate immune system.  
 
TLR2 
TLR2 plays a key role in the detection of Gram-positive organisms through its 
recognition of various microbial components and has been shown to interact physically 
and functionally with TLR1 and TLR6. TLR1 and TLR2 are co-expressed on cells of the 
innate immune system, including macrophages and dendritic cells (Ochoa et al., 2003). 
This study also showed expression of both TLRs by tonsillar epithelial cells, suggesting 
that mucosal epithelial cells may play a role in microbial recognition. TLR1 and TLR2 
appear to recognise soluble factors, porins and lipoproteins (Texereau et al., 2005). 
Lipoteichoic acid activates immune cells via the TLR2/TLR6 heterodimer (Ozinsky et 
al., 2000; Takeuchi et al., 2001, 2002).  Peptidoglycan has been reported as a TLR2 
ligand, however, it has been suggested that such activity is due to the presence of 
lipopeptide contamination (Travassos et al., 2004). A number of studies have 
demonstrated that TLR2-deficient (TLR2
-/-
) mice are very susceptible when challenged 
with Staphylococcus aureus, Streptococcus pneumoniae and Mycobacterium 
tuberculosis (Drennan et al., 2004; Echchannaoui et al., 2002; Takeuchi et al., 2000), 
illustrating the importance of TLR2 in host defence against Gram-positive and acid-fast 
organisms. In addition, in a model utilising TLR2 null mice, Citrobacter rodentium-
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induced colitis is exacerbated. These mice display impaired epithelial barrier function 
suggesting that TLR2 signalling in immune cells may be involved in the maintenance of 
mucosal integrity (Gibson et al., 2008; Pull et al., 2005).  
A polymorphism in the human TLR2 gene (Arg753Gln) is associated with a reduced 
response to bacterial lipoproteins and increased susceptibility to staphylococcal infection 
(Lorenz et al., 2000) and tuberculosis (Ogus et al., 2004).  In the latter study it was 
reported that the risk of developing TB was 6-fold higher in individuals homozygous for 
the variant allele and 1.6-fold higher for heterozygotes. 
 
TLR5 
TLR5 is expressed by monocytes, immature dendritic cells and on the basolateral 
surfaces of epithelial cells (Akira et al., 2006) and detects flagellin, the major protein 
constituent of flagella. Approximately 10% of Caucasian individuals carry a single 
nucleotide polymorphism (SNP), TLR5392STOP, that introduces a stop codon into the 
ligand-binding domain. This dominant mutation results in a truncated receptor with 
severely impaired signalling capability and is associated with a susceptibility to 
Legionnaires’ disease (Hawn et al., 2003). 
 
IL-8 
As discussed in section 1.9.2 colitis is characterised by a massive influx of neutrophils 
into the colonic mucosa, while the pseudomembranes of PMC are rich in neutrophils 
(Souza et al., 1997). IL-8 is a potent chemoattractant for neutrophils and its role in the 
pathogenesis of CDI has been the subject of a number of studies. Steiner et al., (1997) 
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reported that faecal IL-8 concentrations were significantly higher in patients with 
moderate to severe CDI than in those with mild disease. Jiang et al., ( 2006, 2007) 
examined the relationship between susceptibility to CDI and genetically determined 
variations in the production of IL-8. These studies demonstrated that a SNP (-251 A/A 
genotype) in the IL-8 promoter region was associated with increased susceptibility to 
CDI and with increased faecal IL-8 concentrations.  
 
The aim of this study was to establish the prevalence of these TLR2, TLR5 and IL-8 
SNPs within the study population and to determine whether an association existed 
between these genotypes and susceptibility to CDI.  
 
5.2 Results 
DNA was extracted from paraffin wax-embedded tissue specimens using the Chelex-
100/thermocycler method as described in 2.4.1. Twenty two specimens were treated as 
outlined, including three biopsies which were not subject to immunohistochemical 
staining as the architecture and/or cell composition of the tissue samples were 
predominantly abnormal.  It was considered appropriate to use these samples as it was 
thought unlikely that the abnormalities seen would reflect changes in the genes under 
examination. The method of DNA extraction used does not have a 100% success rate; 
however, DNA was successfully extracted from 19 specimens, the three biopsies among 
them. Genotypes were determined by PCR as previously described; the results are 
shown in Table 5.1 and representative gels are shown in Appendix 2. In seven instances 
a PCR product was not obtained despite repeated attempts; the absence of a result is 
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indicated by an asterisk. An IL-8 genotype could not be obtained in four instances (two 
carriers, one case and one control); a TLR2 genotype in one instance (control) and a 
TLR5 genotype in two instances (one case and one control). Given the small sample size 
for each study population no formal statistical analysis has been carried out. The 
polymorphic variants are as follows: IL-8 A allele; TLR2 A allele and TLR5 T allele. 
 
Study Participant Study Group Genotypes Comments 
  IL-8 TLR2 TLR5  
AW81 Case AT GG *  
AW89 Case AT GG CC  
AW95 Case AT GG CT  
AW96 Case AT GG CC  
AW97 Case AA GA CT  
AW98 Case * GG CC  
AW7 Carrier AA GG CC Biopsy tissue unstained 
AW21 Carrier AT GG CC Biopsy tissue unstained 
AW57 Carrier TT GG CC  
AW82 Carrier AT GG CC  
AW88 Carrier * GG CC  
AW106 Carrier * GG CC  
AW107 Carrier AT GA CC  
AW108 Carrier AA GG CC  
AW4 Control AT GG CC  
AW6 Control AT GG CC  
AW31 Control AT GG CC Biopsy tissue unstained 
AW42 Control * GG *  
AW75 Control AT * CC  
 






The variant genotype associated with increased susceptibility to CDI (-251A/A) was 
present in 20% of cases (1/5) and 33% of carriers (2/6). No control subjects carried this 
genotype. One carrier was homozygous for the wild-type allele with the remainder of the 
study population being heterozygous. Allele frequencies for A and T were found to be 
0.6 and 0.4 in the case group, 0.58 and 0.42 in the carrier group and 0.5 and 0.5 in the 
control group, respectively.  
 
TLR2 genotypes 
No individuals homozygous for the variant allele were identified. Two heterozygotes 
were identified; one of six cases (17%) and one of eight carriers (12.5%). No control 
subjects carried the variant allele. Allele frequencies for G and A were found to be 0.92 
and 0.08 in the case group and 0.94 and 0.06 in the carrier group, respectively.  
 
TLR5 genotypes 
Two individuals heterozygous for the dominant variant allele were identified; both were 
cases (2/5; 40%). The variant allele was not carried by any carrier or control subjects. 
The allele frequencies for C and T were 0.8 and 0.2 in the case group, respectively. 
 
Returning to those three individuals carrying the IL-8 variant genotype associated with 
an increased susceptibility to CDI, it can be seen that the one case with this genotype is 
heterozygous for both the TLR2 and TLR5 variant alleles. The two carriers with this 
genotype are both homozygous for the wild-type TLR2 and TLR5 alleles.  
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5.3 Discussion 
Given the small number of study participants it is not possible to determine whether 
statistically significant differences exist between the study groups in terms of genotypes. 
Furthermore, the small data set mandates that comparisons with published data should 
be considered with caution. It is, however, possible to draw inferences from the data and 
put forward suggestions for future research. 
Of the three polymorphisms examined in this study published data regarding an 
association with susceptibility to CDI relate solely to the IL-8 variant genotype. In this 
study the variant genotype was found only in cases and carriers, being carried by 20% 
and 33% respectively. Jiang et al., (2006) reported the presence of the variant genotype 
in a higher percentage of cases (39%, 15/38) and among the control group (16%, 12/73). 
Allele frequencies in this study and that of Jiang et al., were, however, very little 
different. Frequencies for A and T in the case group were 0.6 and 0.4 respectively, in 
both studies. In the control group frequencies were 0.5 and 0.5 in this study and 0.49 and 
0.51 in that of Jiang et al. The study by Jiang et al., did not look at carriers but the 
authors hypothesised that IL-8 genotype would not relate to asymptomatic infection. The 
data presented here would suggest that this may not be the case given that the variant 
genotype was more prevalent in the carrier group and allele frequencies at 0.58 and 0.42 
differ very little from those of the case group. The finding of a comparable prevalence of 
the variant genotype among carriers suggests that additional impairments of the host 
immune response must prevail within an infected individual for symptoms to develop. In 
their second study Jiang et al., (2007) examined the relationship between IL-8 
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polymorphism and serum levels of IgG anti-toxin A in CDI cases and controls. They 
reported that individuals with CDI carrying the IL-8 A/A genotype were significantly 
more likely to show an impaired humoral immune response to toxin A than those 
individuals with CDI not carrying this genotype. In the present study it was found that 
the one case carrying the IL-8 -251 A/A genotype was heterozygous for the TLR5 
dominant variant allele while the two carriers with this genotype were both homozygous 
for the wild-type TLR5 allele. Furthermore, the data suggest that the presence of the 
TLR5 variant allele alone may predispose to CDI given that the second case carrying 
this variant carried the IL-8 -251 A/T genotype.  
 
The data presented here show that the TLR2 variant A allele has a low frequency within 
the study population as a whole. The study by Ogus et al., (2004) reported that the A 
allele was present in 17.9% of TB patients and 7.7% of controls. Allele frequencies for 
G and A were found to be 0.86 and 0.14 among TB cases and 0.95 and 0.05 among 
controls. Allele frequencies identified within the present study are much closer to those 
of the Ogus control group. The two individuals carrying the variant allele, both 
heterozygotes, were a case and a carrier suggesting the possibility that the polymorphism 
is associated with infection but not necessarily symptomatic disease.  
 
Given that the polymorphisms under investigation are relatively rare a much larger study 
population than that examined here would be required to ensure sufficient power to 
detect statistically significant differences between the study groups. The data presented 
here show that variant genotypes were found only in cases and carriers although the 
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sample size is too limited to permit inferences to be drawn about association of the 












6. Mechanisms of moxifloxacin resistance and 




The use of fluoroquinolones in clinical practice is widespread and it has been suggested 
that their use in hospitals could be increasingly responsible for outbreaks of CDI for two 
reasons (Gerding, 2004). Firstly, the newer fluoroquinolones have greater activity 
against anaerobes and are therefore more likely to disrupt normal flora. Secondly, they 
may exert selective pressure favouring the emergence of fluoroquinolone-resistant 
strains during antibiotic treatment and the subsequent proliferation of resistant isolates. 
Moxifloxacin resistance has been found to be prevalent in clinical strains of C. difficile 
in the Edinburgh area of Scotland; a recent characterisation study by our group found 
that 87% of the strains tested were resistant to this antibiotic (Mutlu et al., 2007). 
Resistance to fluoroquinolones is mediated by different mechanisms including mutations 
of DNA gyrase (the subunits of which are encoded by gyrA and gyrB) and 
topoisomerase IV genes (parC and parE), reduced permeability and the presence of 
efflux pumps (Higgins et al., 2003). Analysis of its genome has shown that C. difficile, 
in common with organisms such as Treponema pallidum and Helicobacter pylori, lacks 
the genes for topoisomerase IV (Dridi et al., 2002). Fluoroquinolone resistant isolates of 
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C. difficile characterised to date have shown amino acid changes in the quinolone 
resistance determining region (QRDR) of GyrA and GyrB. Efflux pumps are involved in 
antimicrobial resistance in many species of bacteria, however, as discussed in section 
1.10, little is known as yet about the role of efflux pumps in multidrug resistance in C. 
difficile. Two genes have been shown to confer to resistance to certain chemical 
compounds: cdeA (C. difficile efflux), having homology to members of the MATE 
(multidrug and toxic compound extrusion) family of efflux pumps (Dridi et al., 2004); 
and cme (Clostridium multidrug efflux), homologous to members of the major facilitator 
superfamily (Lebel et al., 2004).  
 
Immediately upstream of cme in the C. difficile genome is a gene designated CD3197, a 
putative MerR family transcriptional regulator. Members of this family have been shown 
to activate suboptimal sigma 70-dependent promoters in which the -35 and -10 elements 
are separated by more than the optimal 17+/-1 bp (Brown et al., 2003). Transcription is 
activated through protein-mediated DNA distortion and the majority of MerR regulators 
respond to environmental stressors such as the presence of antibiotics.  
 
6.2 Aims 
Given the possible importance of fluoroquinolone resistance in the aetiology of CDI the 
first aim of this study was to examine the mechanisms of moxifloxacin resistance in our 
collection of clinical strains (Mutlu et al., 2007) and also in a moxifloxacin mutant, with 
reduced susceptibility, derived from a sensitive parent strain. The study focused on the 
 90 
analysis of the gyrA and gyrB genes and looked in greater depth than previous studies at 
a possible role for cme and cdeA by examining gene expression.  Overexpression of such 
genes may result from the presence of mutations within the promoter region of the 
genes’ transcriptional regulator(s) or within the regulator(s) themselves. Therefore 
CD3197, a putative regulator of cme, and its promoter region were also examined.   
 
It was hypothesised that the competitive advantage conferred by resistance to 
moxifloxacin may influence the fitness of C. difficile strains, in particular growth and the 
expression of the virulence factors toxins A and B. Thus the second aim of this study 
was to determine whether a correlation exists between fitness and resistance or 
sensitivity to moxifloxacin.   
 
6.3 Materials and methods 
Twenty eight strains, 14 resistant and 14 sensitive, were selected from the strain 
collection and MICs confirmed by the agar dilution method. The gyrA, gyrB and tcdC 
genes were analysed by PCR amplification and DNA sequencing. Toxin production was 
examined by means of semi-quantitative RT-PCR amplification of tcdA and tdcB; all 
such RT-PCRs were normalised by comparison with the products of amplification of a 
region of the 16s rRNA gene, which is transcribed at high levels throughout the 
exponential and stationary phases of growth. For each experiment the same cDNA 
preparation was used as the template for analysis of both the gene of interest and 16s 
expression. Toxin production was further examined by measurement of toxin 
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concentration in the growth medium by ELISA. The data from pilot experiments, 
reported in section 6.4.3, identified 16 hours (early/mid stationary phase) and 24 hours 
(late stationary phase) post-inoculation as appropriate time points for analysis.  
The roles of cme and cdeA were examined by analysing gene expression through semi-
quantitative RT-PCR. The time points of 16 and 24 hours post-inoculation were again 
chosen for analysis following pilot experiments reported in section 6.4.2. CD3197 and 
its putative promoter region were amplified by PCR for a selection of strains, sequenced 
and compared with those of reference strain 630. All procedures are described more 





Mechanisms of moxifloxacin resistance 
 
6.4.1 MICs and gyrA and B sequencing 
 
MICs for moxifloxacin were determined for 28 strains and are shown in Table 6.1. All 
resistant (MIC ≥ 16 µg ml
-1 
) strains tested, with the exception of EM47 which has 
intermediate resistance, carry the common gyrA mutation ACT→ATT (Thr82→Ile) 
(Ackermann et al., 2001). This mutation is not present in any sensitive strains. EM47 












gyrA mutation gyrB mutation 
EM23 001 32 Thr82→ Ile N 
EM24 001 16 Thr82→ Ile N 
EM27 001 16 Thr82→ Ile N 
EM28 001 16 Thr82→ Ile N 
EM30 001 32 Thr82→ Ile N 
EM31 001 32 Thr82→ Ile N 
EM47 070 8 N N 
EM57 106 32 Thr82→ Ile N 
EM58 106 32 Thr82→ Ile N 
EM64 106 32 Thr82→ Ile N 
EM82 106 64 Thr82→ Ile N 
EM125 106 16 Thr82→ Ile N 
EM184 001 16 Thr82→ Ile N 
EM186 001 16 Thr82→ Ile N 
     
EM5 023 2.5 N N 
EM14 014 2 N N 
EM36 042 2 N N 
EM83 002 1.5 N N 
EM84 070 2.5 N N 
EM87 005 1.5 N N 
EM96 005 1.5 N N 
EM102 001 1 N N 
EM109 049 1.5 N N 
EM120 002 2 N N 
EM126 005 1 N N 
EM130 106 1.5 N N 
EM169 020 2 N N 
EM185 013 0.25 N N 
 









Figure 6.1 shows the nucleotide (a) and amino acid sequence (b) of the amplified 
fragment of gyrA for EM28 (resistant) and EM96 (sensitive) aligned with those of 630. 





              Figure 6.1 (a). Nucleotide sequence of sense strand gyrA fragment of EM28 and EM96 aligned with that 
of 630 (sensitive). Fragment comprises nucleotides 74-264 of gyrA. The ACT→ATT mutation present in 







  Figure 6.1 (b). Amino acid sequence of GyrA fragment of EM28 and EM96 aligned with that of 630. 





Single passage mutant 
 
A moxifloxacin mutant of a sensitive parent strain was isolated as follows. An overnight 
culture of EM96 (MIC 1.5 µg ml
-1
) was grown up in pre-reduced thioglycollate medium 
as described in section 2.5.10. 100µl of neat culture were spread onto Brucella agar 
plates containing 1.5 µg ml
-1
, 2 µg ml
-1 
or 3 µg ml
-1 
moxifloxacin.  After 48 hours 
colonies were picked and subcultured to pre-reduced thioglycollate medium overnight 
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prior to their MICs being determined. The colony with the highest MIC was identified 
and further passaged on plates containing increasing concentrations of moxifloxacin. An 
isolate designated EM96-R with an MIC of 6.5µg ml
-1
was isolated. Sequencing of gyrA 
and gyrB genes of EM96-R did not reveal the presence of the Thr82→Ile mutation in 
gyrA nor any common mutations in gyrB. Analysis of the amino acid sequences of the 
GyrA and GyrB proteins revealed no differences between the parent, 630 and EM96-R. 
 
 
6.4.2 Investigation of possible role of efflux pumps cdeA and cme in 
moxifloxacin resistance 
 
Expression of cdeA 
EM28, EM125, EM47, EM96 and EM96-R were grown up on two separate occasions, 
as described in section 2.5.2. Semi-quantitative RT-PCR products were present at 16 
hours post-inoculation for only one strain, EM28, in one experiment only (Figure 6.2, 
lane 8), suggesting that this gene is not involved in resistance to moxifloxacin in this 





Expression of cme 
 
Pilot semi-quantitative RT-PCR experiments with EM28 (resistant) and EM102 
(sensitive) examining expression of this gene at 16 hours (early/mid stationary phase) 
and 24 hours (late stationary phase) post-inoculation indicated that identifiable 
differences existed between the two strains. At 16 hours expression by EM28 was higher 
than that seen in EM102; by 24 hours reduced expression by EM28 was seen, equivalent 
to that seen in EM102 (Figure 6.3a).  Analysis of expression was normalised by 
examination of 16s gene expression; a representative gel of this standard is shown as 
Figure 6.3d confirming that equivalent levels of cDNA are present for each strain at each 
time point.  These time points were utilised in subsequent experiments. The pattern of 
expression seen in the pilot experiment was not replicated in two further experiments. In 
the first (Figure 6.3b) no expression was seen for either strain at both 16 and 24 hours 
post-inoculation and in the second (Figure 6.3c) expression was seen only for EM28 at 
16 hours post-inoculation, as evidenced by the 198bp band in lane 6. 
Figure 6.2. RT-PCR amplification of cdeA gene, 
fragment size 560bp.  Lanes 1 and 13 100bp ladder 
(Promega). Lane 2 EM96-R (int), lane 3 EM96 (S), 
lane 4 EM47 (int), lane 5 EM28 (R), lane 6 EM125 
(R), lane 7 EM96-R (int), lane 8 EM28 (R), lane 9 
EM47 (int), lane 10  EM125 (R), lane 11 630 gDNA 
(positive control), lane 12 negative control.  
Int = intermediate susceptibility, S=sensitive, 
R=resistant.  
      1   2   3   4  5   6   7  8   9  10 11 12 13 
500bp 
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      (a)            (b)      
 
 

















In order to obtain a clearer picture expression in a larger selection of strains was 
examined. Figure 6.4 shows expression at 16 hours post-inoculation in six strains (three 
resistant and three sensitive including EM28 and EM102). The data suggest that 
expression in two of the three sensitive strains (lanes 3, 4 and 5) was lower than that 
seen in the resistant strains (lanes 2, 6 and 7).  
 
500bp 
Figure 6.3 (a), (b), (c). RT-PCR amplification of cme gene, fragment size 198 bp.  Lanes 1 and 8 100bp 
ladder (Invitrogen or Promega), lane 2 EM28 at 16 hours, lane 3 EM102 at 16 hours, lane 4 EM28 at 24 
hours, lane 5 EM102 at 24 hours, lane 6 630 gDNA, lane 7 negative control.  
 
(d) representative 16s standards for experiment (c), fragment size 433bp. Lane 1 100bp ladder; lane 2 
EM28 at 16 hours; lane 3 EM102 at 16 hours; lane 4 EM28 at 24 hours; lane 5 EM102 at 24 hours; lane 
6 negative control. 
600bp 
  1     2    3    4     5    6      7    8 
1      2       3     4      5     6 
1     2    3    4     5     6     7   8 





Figure 6.5 shows expression in EM28, EM125, EM96 and also EM47 (intermediate 
resistance) and EM96-R in two separate experiments. As in previous experiments, 
expression was seen for EM28 and EM125. A level of expression comparable to these 
resistant strains was seen for EM47 but no expression was detectable for EM96-R or its 
parent EM96.  
 
  (a)                 (b) 
Figure 6.5. RT-PCR amplification of cme gene fragment in two separate experiments.   
 
(a) Lanes 1 and 9 100bp ladder (Promega). Lane 2 EM28 (band present), lane 3 EM96, lane 4 
EM125 (band present), lane 5 EM96-R, lane 6 EM47 (band present), lane 7 630 gDNA, lane 8 
negative control.  
 
(b) Lanes 1 and 13 100bp ladder (Promega). Lane 2 EM96-R, lane 3 EM28 (band present), lane 
4 EM125 (band present), lane 5 EM47 (band present), lane 6 EM125 (band present), lane 7 
EM28 (band present), lane 8 EM47 (band present), lane 9 EM96, lane 10 EM96-R, lane 11 630 
gDNA, lane 12 negative control.  
Figure 6.4. RT-PCR amplification of cme gene 
fragment.  Lanes 1 and 10 100bp ladder (Promega). 
Lane 2 EM28, lane 3 EM96 (S), lane 4 EM102, lane 
5 EM120 (S), lane 6 EM125 (R), lane 7 EM184 (R), 
lane 8 630 gDNA, lane 9 negative control.  
 
500bp 
    1  2   3   4   5   6  7   8   9  10 
  1   2   3  4   5   6   7   8  9 
    1   2  3  4  5   6   7  8  9  10 11 12 13 
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Analysis of the MerR family transcriptional regulator CD3197 and its putative 
promoter region 
 
The semi-quantitative analysis of cme expression described above suggested a possible 
association between overexpression of this gene and reduced susceptibility to 
moxifloxacin. Expression of efflux pumps under normal growth conditions is tightly 
controlled in the absence of mutations in their regulatory mechanisms. Analysis of the 
putative transcriptional regulator of cme, CD3197, and its promoter region (Figure 6.6) 
was therefore undertaken to determine if any such mutations could be identified and 
whether their presence was associated with overexpression of cme.   
 
Figure 6.6.  Diagrammatic representation of the cme locus in C. difficile 630. CD3197 is the putative 
regulator of cme, the efflux pump gene. Coloured boxes indicate direction of transcription. Nucleotide 
regions sequenced are indicated by blue and green arrows. The region in which repeat unit insertions and 
deletions are found is indicated by a red arrow.  
 
The locus was amplified and sequenced for seven moxifloxacin resistant and five 
sensitive strains, together with EM47 and EM96-R. Nucleotide and amino acid 
sequences of the amplified fragments were compared with those of reference strain 630. 
In all strains the CD3197/cme region did not differ from that of the reference strain, 
         CD3196 
 
3741534 - 3742496 
      CD3197 
 
3742649 - 3743395 
        cme 
 
3743481 - 3744731 
3742307 - 3742967 
3742660 - 3743571 
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however, upstream of CD3197 three genotypic variants were identified: a 95p insertion, 
a 19bp deletion and a 38bp deletion, illustrated in Figures 6.7, 6.8 and 6.9. The deletions 
and insertion involve a 19bp forward repeat sequence (TCATAAACTAATTACTCTT) 
that appears three times in tandem in the genome of strain 630, 25bp downstream of the 
start of the -10 promoter element and 145bp upstream of the open reading frame of 
CD3197. A forward repeat is a DNA fragment appearing twice or more in the same 
orientation and on the same strand. In the case of the 95bp insertion the sequence is 
repeated in tandem four times in full and twice partially (Figure 6.8b).   
 
Figure 6.7. Diagrammatic representation of promoter repeat region, indicated by 







         CD3196 
3741534 - 3742496 
        CD3197 
3742649 - 3743395 





Figure 6.8a. Nucleotide sequences of the CD3197 promoter region of EM83 and EM126 
compared with that of reference strain 630 (nucleotides 3742376 – 3742674). Three tandem 
repeats of the 19bp sequence are found in 630 between nucleotides 131 and 187 (underlined). 
Two repeats are found in EM126 and one in EM83. The putative -35 and -10 promoter 
sequences begin at positions 88 and 107 respectively (underlined). The open reading frame of 







Figure 6.8b. Nucleotide sequence of the CD3197 promoter region of EM31 compared with that 
of reference strain 630 (nucleotides 3742376 – 3742676), showing 95bp insertion. The three 
tandem repeats present in 630 are found between nucleotides 130-134 and 230-281 (underlined). 
The putative -35 and -10 promoter sequences begin at positions 87 and 106 respectively 






Figure 6.9. Diagrammatic representation of repeat sequence insertions and deletions in 
the promoter region of CD3197. Yellow boxes – partial repeats; turquoise boxes – 
complete 19bp repeats; red box – 95bp insertion of repeat sequences; deletions are 
indicated by a black line. The start of the ORF for CD3197 is indicated by an arrow.  
 
 
A BLAST analysis of the 19bp repeat sequence, using low-stringency parameters, did 
not identify any homologous sequences in other bacterial genomes.   
 










Strain Moxifloxacin susceptibility Ribotype Variant 
630 Sensitive 012 Wild-type 
(three tandem repeats) 
EM31 Resistant 001 95bp insertion 
EM102 Sensitive 001 95bp insertion 
EM24 Resistant 001 95bp insertion 
EM28 Resistant 001 95bp insertion 
EM83 Sensitive 002 38bp deletion 
EM126 Sensitive 005 19bp deletion 
EM96-R Intermediate 005 19bp deletion 
EM96 Sensitive 005 19bp deletion 
EM64 Resistant 106 Wild-type 
EM84 Sensitive 070 Wild-type 
EM57 Resistant 106 Wild-type 
EM82 Resistant 106 Wild-type 
EM47 Intermediate 070 Wild-type 
EM125 Resistant 106 Wild-type 
 
Table 6.2. Prevalence of promoter region variant genotypes among sequenced strains. EM96-R is a 
moxifloxacin mutant derived from EM96.  
 
EM96-R and its parent, EM96, carry the 19bp deletion, suggesting that the selective 
pressure exerted by moxifloxacin does not impact on this region of the genome. 
 
Semi-quantitative analysis of cme expression was undertaken for those sequenced strains 
not previously examined (data not shown). The sequencing results and all expression 
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data obtained do not support an association between the presence of a variant genotype 
and overexpression of cme. Of those strains carrying a variant genotype only EM28 has 
been shown to overexpress this gene. Furthermore the data obtained from analysis of 
this further group of strains do not support a role for cme in moxifloxacin resistance as 
no differences in expression were seen between the resistant and sensitive strains. Given 
the limited number of strains tested these findings may reflect a type II statistical error, 
i.e. the sample size lacks sufficient power to detect a statistically significant difference. 
 
Moxifloxacin resistance and fitness 
 
6.4.3 Analysis of toxin production 
 
tcdC sequencing   
    
As discussed in section 1.8.4, TcdC is a negative regulator of tcdA and tcdB expression. 
Mutations in tcdC have been identified that may alter the protein’s functionality 
resulting in overexpression of toxins. To exclude the possibility that such mutations 
were influencing toxin production by the strains under examination the sequenced 
fragments were compared with that of reference strain VPI10463. Readable sequences 
were obtained for 24 strains. Repeated attempts were made to obtain sequences for all 
strains, however, cost and time constraints meant that was not achieved. Sequences were 
not obtained for EM5, EM14, EM36 and EM120, all sensitive strains. Analysis of the 
sequence of the amplified fragments showed that none of the most common variant 
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genotypes identified (Curry et al., 2007; Spigaglia & Mastrantonio, 2002) was present in 
any strain. Figure 6.10 shows a representative sequence, from EM83, aligned with that 




Figure 6.10 (a). Nucleotide sequence of tcdC fragment of EM83 aligned with that of VPI10463. Only that 




   





Pilot experiments were carried out using one resistant strain (EM28) and one sensitive 
strain (EM102) to determine appropriate time points for sampling. Figure 6.11 shows the 
growth curve of the two strains over a 48 hour period expressed as OD values; little 
difference in the rate of growth or maximum OD was observed between the two strains.  
OD measured at 600nm has been shown previously to correlate with viable counts 
(Drummond & Poxton, 2003b).  
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Figure 6.11. Growth curves for EM28 and EM102 expressed as OD600 values. Strains were grown up in 
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Figure 6.12. Toxin production by EM28 and EM102 as measured by Toxin A + B ELISA (TechLab) and 




It can be seen that the two strains differ in their pattern of toxin production. EM28 starts 
producing toxins after 8 hours and the level is close to its peak by 16 hours. In 
comparison, EM102 starts producing toxins after 16 hours and reaches an equivalent 
level to EM28 after 48 hours. The apparent fall in the level of toxins produced by EM28 
at 24 hours is likely to be an experimental anomaly or reflects breakdown of the toxins 
or their complexing with other molecules in the growth medium. The greatest difference 
in toxin production is seen at 16 hours post-inoculation, during early/mid stationary 





Expression of tcdA and tcdB  
Initial experiments using EM28 and EM102 indicated that expression of both tcdA and 
tcdB was higher at 16 hours in EM28. By 24 hours post-inoculation (late stationary 
phase) expression in this strain had reduced and was comparable to that seen in EM102 
(Figure 6.13).  
 
         
(a)                                                                                    (b) 
Figure 6.13. RT-PCR amplification of tcdA and tcdB fragments. (a). Lanes 1 and 14 100bp 
ladder (Invitrogen), lanes 2-7 tcdA (624bp): lane 2 EM28 at 16 hours, lane 3 EM102 at 16 
hours, lane 4 EM28 at 24 hours, lane 5 EM102 at 24 hours, lane 6 630 gDNA, lane 7 negative 
control. Lanes 8-13 tcdB (412bp): lane 8 EM28 at 16 hours, lane 9 EM102 at 16 hours, lane 10 
EM28 at 24 hours, lane 11 EM102 at 24 hours, lane 12 630 gDNA, lane 13 negative control.   
 
(b). Lanes 2 and 18 100bp ladder (Promega). Lanes 2-11 tcdB (412bp): lane 2 EM28 at 16 
hours, lane 3 EM102 at 16 hours, lane 4 EM28 at 24 hours, lane 5 EM102 at 24 hours, lanes 6-9 
RNA preps, lane 10 630 gDNA, lane 11 negative control. Lanes 12-17 tcdA (624bp): lane 12 
EM28 at 16 hours, lane 13 EM102 at 16 hours, lane 14 EM28 at 24 hours, lane 15 EM102 at 24 




 600bp  
500bp 
tcdA tcdB 
   1  2   3   4   5  6   7   8   9 10  11 12 13 14 
         1   2  3  4   5  6   7   8  9  10 11 12 13 14 15 16 17 18 
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These findings were not replicated in subsequent experiments. Figure 6.14 reveals a 
reversed position with EM28 showing a lower level of expression of both genes at both 
time points. When tcdA and tcdB expression in EM47 (intermediate resistance), EM96 
(sensitive) and EM125 (resistant) was examined, greater levels of expression were seen 
in the intermediate and sensitive strains at 16 hours post-inoculation (Figure 6.15).   
 
        
(a)                                                 (b) 
Figure 6.14. (a). RT-PCR amplification of tcdA. Lane 1 100bp ladder (Promega). Lane 2 EM28 
at 16 hours, lane 3 EM102 at 16 hours, lane 4 EM28 at 24 hours, lane 5 EM102 at 24 hours, lane 
6 630 gDNA, lane 7 negative control.  
 
(b). RT-PCR amplification of tcdB. Lanes 1 and 8 100bp ladder (Promega). Lane 2 EM28 at 16 
hours, lane 3 EM102 at 16 hours, lane 4 EM28 at 24 hours, lane 5 EM102 at 24 hours, lane 6 
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A final experiment in which three sensitive strains (EM96, EM102 & EM120) and three 
resistant strains (EM28, EM125 & EM184) were cultured simultaneously demonstrated 
no obvious trend in expression between the two groups of strains at 16 hours post-





Figure 6.15.  RT-PCR 
amplification of tcdA and tcdB 
fragments. Lanes 1 and 12 100bp 
ladder (Promega). Lanes 2-6 tcdA 
(624bp): lane 2 EM47, lane 3 
EM96, lane 4 EM125, lane 5 630 
gDNA, lane 6 negative control. 
Lanes 7-11 tcdB (412bp): lane 7 
EM47, lane 8 EM96, lane 9 
EM125, lane 10 630 gDNA, lane 
11 negative control.  
 
Figure 6.16. RT-PCR amplification 
of tcdA and tcdB fragments. Lanes 1 
and 18 100bp ladder (Invitrogen). 
Lanes 2-9 tcdA (624bp): lane 2 
EM28, lane 3 EM96, lane 4 EM102, 
lane 5 EM120, lane 6 EM125, lane 7 
EM184, lane 8 630 gDNA, lane 9 
negative control. Lanes 10-17 tcdB 
(412bp): lane 10 EM28, lane 11 
EM96, lane 12 EM102, lane 13 
EM120, lane 14 EM125, lane 15 
EM184, lane 16 630 gDNA, lane 17 
negative control.  
 
  2    3    4     5      6     7      8    9    10  11  12   13   14    15  16   17   18   
  1     2    3     4     5     6     7    8     9    10  11   12 
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Taken as a whole these experiments indicate that there is no reproducible difference in 
the expression of tcdA and tcdB between resistant and sensitive strains in early/mid 
stationary phase. 
 
Measurement of toxin production by ELISA 
Two separate experiments were performed. All 28 strains for which the gyrA and gyrB 
genes had been sequenced were grown up in PPY with the growth medium sampled 16 
hours post-inoculation and toxin concentration determined by ELISA, as described in 
section 2.5.3. The mean of the two readings was taken and toxin production by the two 
groups of strains was compared by means of a Mann-Whitney test. The data are shown 
in Figure 6.17.  Sensitive strains have a greater interquartile range (1.46 vs. 1.08), 
however, median values are little different between sensitive and resistant strains (0.29 
and 0.45 respectively; p=0.8). 
















Figure 6.17. Comparison of toxin production 16 hours post-inoculation by resistant (n=14) and sensitive 
strains (n=14) as measured by ELISA and expressed as OD450 values. Boxes represent the range between 
quartile 1 and quartile 3, with the median value represented by the horizontal line. The whiskers indicate 
highest and lowest values.  
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If the data are analysed excluding those strains for which no tcdC sequence could be 
obtained the picture is little different (Figure 6.18). Sensitive strains now have a smaller 
interquartile range than resistant (0.77 vs. 1.08) but the median value is reduced only 
marginally to 0.26. There remains no statistically significant difference between the two 

















Figure 6.18. Comparison of toxin production 16 hours post-inoculation by resistant (n=14) and sensitive 
strains (n=10, excluding those without sequenced tcdC fragment) as measured by ELISA and expressed as 
OD450 values. Boxes represent the range between quartile 1 and quartile 3, with the median value 
represented by the horizontal line. The whiskers indicate highest and lowest values, with outliers indicated 




Correlation between transcription and toxin production as measured by ELISA 
 
The data obtained in this study are insufficient to determine whether a correlation exists 
in the strains under examination between transcription of tcdA and tcdB and toxin 
production as measured by ELISA. Levels of transcription were ascertained at one, or in 
some instances two, time points only. The concentration of toxin present in the growth 
medium at those time points, as measured by ELISA, does not reflect transcription at 
that point alone; the growth culture is a closed system and toxin concentration therefore 
reflects transcription, translation and secretion from inoculation to the point of sampling.  
 
6.4.4 Growth comparisons 
 
The growth of four resistant and four sensitive strains, as measured by OD, was recorded 
over a 24 hour period (Figure 6.19). With the exception of EM83 (sensitive) there is 
little discernable difference in growth between the sensitive and resistant strains.  
 
The mean OD values for the two groups of strains at each time point are shown in Figure 
6.20.  The data suggest that growth occurs more rapidly and to a higher level in sensitive 
strains, however, the difference is not significant (p=0.2) and may be skewed by the 
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Figure 6.19. Growth expressed as OD600 values over a 24 hour period. (R = resistant, S = sensitive.). Each 





















Figure 6.20. Growth expressed as averaged OD600 values for resistant and sensitive strains. Error bars 
represent the standard error of the mean.  
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A further study comparing the growth of EM96-R and its parent EM96 over a 24 hour 
period showed that the mutant grew more rapidly and achieved higher OD values than 
did the parent, indicating that the fitness of the mutant was not impaired by its reduced 




















Figure 6.21. Comparative growth of EM96-R and its parent EM96, expressed as OD600 values. Each data 





6.5.1 Mechanisms of moxifloxacin resistance 
 
As noted in the introduction to this chapter, fluoroquinolone resistant strains of C. 
difficile characterised to date have shown amino acid changes in the quinolone resistance 
determining region of GyrA and GyrB. GyrB mutations are less common than GyrA and 
tend to confer low levels of resistance (Spigaglia et al., 2008). The GyrA amino acid 
substitution Thr82→ Ile has been reported by a number of groups (Ackermann et al., 
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2001; Dridi et al., 2002; Drudy et al., 2007; Schmidt et al., 2007; Spigaglia et al., 2008). 
This mutation has been demonstrated in all ribotype 027 strains characterised so far 
(Drudy et al., 2007; Spigaglia et al., 2008). Thr82 corresponds to Ser83 in Escherichia 
coli, the mutation of which alters the structure of the quinolone binding site near the 
interface of the enzyme and DNA (Hooper, 1999). Drudy et al., (2006) reported the 
presence of the GyrB substitution Asp426→Val in a cluster of 5 clonal toxin A-
negative, toxin B-positive outbreak strains found to be resistant to five fluoroquinolones. 
Asp426 is thought to be a key site in GyrB; mutations in the corresponding codon in E. 
coli, Staphylococcus aureus and Streptococcus pneumoniae are associated with 
fluoroquinolone resistance (Hooper, 1999). The presence of the GyrA amino acid 
substitution Thr82→ Ile was identified in all the resistant strains examined, with the 
exception of a strain with intermediate resistance and EM96-R. Neither of these strains 
carried a mutation in gyrB, suggesting that reduced susceptibility to moxifloxacin in 
these strains is mediated by a different mechanism. Efflux pumps are known to be 
present in many bacteria and can confer resistance to a variety of molecules, including 
antibiotics, by extrusion (Lebel et al., 2004). It was hypothesised that the cme and cdeA 
genes, both encoding a putative efflux pump, may play a role in reduced susceptibility to 
moxifloxacin; however, the data presented here from experiments examining the 
expression of both genes, do not support this hypothesis.  In the case of cdeA 
overexpression of the gene was seen in one, resistant, strain only. While early 
experiments suggested that overexpression of cme was seen only in those strains 
exhibiting reduced susceptibility to moxifloxacin, these findings were not reproduced in 
subsequent experiments.  
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This study is believed to be the first to examine CD3197, a transcriptional regulator 
located upstream of cme.  Three novel mutations in the putative promoter region of 
CD3197, in the form of tandem forward repeat insertions or deletions, were identified. 
The repeat sequence appears to be unique to C. difficile. Repeat sequences are widely 
found in bacterial genomes and those found within a gene’s regulatory region can 
function as a transcriptional on/off switch (van der Woude & Baumler, 2004). It was 
hypothesised that the presence of these mutations would be associated with 
overexpression of cme; however, the data refute this hypothesis, with only one strain 
with a variant genotype being found to overexpress this gene.  This may be a reflection 
of the position of the repeats, which lie 25bp downstream of the -10 promoter element 
and 145bp upstream of the CD3197 gene start site. Repeat sequences affecting 
transcription levels are more commonly found between the -35 and -10 promoter 
elements (Moxon et al., 1994), where they influence the binding efficiency of RNA 
polymerase.  
 
No association was established between the presence of these mutations and resistance 
or sensitivity to moxifloxacin, with the variant genotypes being present in both sensitive 
and resistant organisms. The conservation of a 19bp deletion in EM96-R further 





6.5.2 Moxifloxacin resistance and fitness 
Studies examining virulence factors and antimicrobial susceptibility in bacterial strains 
have produced conflicting findings. Resistance to quinolones and fluoroquinolones 
among uropathogenic E. coli isolates has been shown to be associated with reductions in 
virulence traits and intrinsically lower virulence strains (Moreno et al., 2006; Horcajada 
et al., 2005). Strains of Pseudomonas aeruginosa overexpressing a type 1 beta-
lactamase were found to be less virulent in a mouse model of acute pneumonia (Ramisse 
et al., 2000). On the other hand, Godoy et al., (2003) found no significant association 
between pathogenicity and antimicrobial susceptibility or resistance among Helicobacter 
pylori clinical isolates. Furthermore, Billstrom et al., (2008) found a significant 
correlation between the presence of the gene encoding the enterococcal surface protein, 
a putative virulence factor, and resistance to ampicillin, ciprofloxacin and imipenem in 
clinical isolates of Enterococcus faecium.  It is believed that the study presented here is 
the first to examine the relationship between fitness, as measured by growth and the 
production of the virulence factors toxins A and B, and susceptibility or resistance to 
moxifloxacin. This study found no correlation between these features, although sensitive 
strains did have a greater range of toxin levels and a higher upper value than the resistant 
strains. However, median values were little different. These results indicate that the 
presence of the moxifloxacin resistance mechanism(s) do not impose a fitness cost.  
In conclusion, this study shows the primary mechanism of resistance to moxifloxacin 
among this population of clinical strains to be the presence of a gyrA mutation that 
results in an amino acid substitution at position 82. However, the absence of this 
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mutation or any mutation in gyrB in two strains of reduced susceptibility suggests that 
fluoroquinolone resistance may be mediated in part by another mechanism. The data 
suggest that the putative efflux pumps encoded by cme and cdeA do not play a role in the 
strains examined.  
 
No association between virulence, as measured by growth and toxin production, and 





This chapter summarises the conclusions drawn from the three studies comprising this 
thesis. Where appropriate suggestions are made as to how these findings could usefully 
be expanded upon. 
 
To reiterate the aims and hypotheses of the three studies: 
 
1. To enumerate immune cell populations within the lamina propria of colonic tissue 
from cases, carriers and controls. It was hypothesised that cases would have fewer 
immune cells than both carriers and controls, while immune cell populations of carriers 
would approximate those of controls. 
 
2. To determine the prevalence of specific host single nucleotide polymorphisms (SNPs) 
in the TLR2, TLR5 and IL-8 genes in the study population and to assess whether their 
presence was associated with susceptibility to CDI.  
 
3. To determine the mechanisms of moxifloxacin resistance in a collection of clinical 
isolates. 
 
4. To determine whether the competitive advantage conferred by resistance to 
moxifloxacin influences the fitness of C. difficile isolates, in particular growth and the 
expression of the virulence factors toxins A and B. 
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Carriers were found to have fewer of all four cell types quantified than both cases 
and controls, while cases had fewer of all cell types than controls.  Multivariate analysis 
of total cell counts, however,  indicated that no statistically significant difference existed 
between the study groups. A larger, prospective study in which a series of faecal and 
tissue specimens were taken prior to and during hospitalisation would be required to cast 
light on the role of the mucosal immune response in determining the outcome of 
infection.  
Despite the lower median cell counts seen in carriers the immune response mounted by 
these individuals is protective against the development of symptomatic colonisation.  To 
understand the nature of this protective response it would be necessary to characterise 
the B and plasma cells in terms of the immunoglobulin class secreted and the antigen-
specificity of the antibodies produced. Characterisation of the antigen-specificity of 
effector CD4
+ 
T cells, particularly the TH2 subtype, would also be required. 
Immunohistochemical staining of tissue samples for immunoglobulin class, particularly 
IgA, is difficult to interpret. Treatment of tissue samples to release individual cells and 
subsequent analysis of these cells by a technique such as FACS (fluorescence-activated 
cell sorting) would be more effective. Antigen-specificity could be determined using a 
technique such as ELISPOT (enzyme-linked immunosorbent spot).  
 
The data are suggestive of an association between the presence of host SNPs and 
increased susceptibility to CDI.  The variant IL-8 and TLR2 genotypes were carried by 
cases and carriers while the variant TLR5 genotype was carried by cases only. No 
variant genotypes were present in control subjects.  Of the three individuals carrying the 
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IL-8 variant genotype associated with an increased susceptibility to CDI, one case with 
this genotype was heterozygous for both the TLR2 and TLR5 variant alleles. The two 
carriers with this genotype were both homozygous for the wild-type TLR2 and TLR5 
alleles.  
 
Published data have demonstrated an association between the variant IL-8 -251 A/A 
genotype and increased susceptibility to CDI when present in conjunction with a further 
immune response defect. This study lends support to those findings with the presence of 
the TLR5
392STOP 
polymorphism representing such a defect. The data are also suggestive 
of an association between the TLR5 polymorphism and CDI when present in isolation. 
The TLR2 variant allele was found only in one case and one carrier, suggesting a 
possible association with infection. The data suggest that a larger study examining the 
presence of the IL-8, TLR2 and TLR5 polymorphisms would be of merit. Analysis of 
the SNPs in conjunction with other aspects of the host immune response, such as serum 
antibody levels and mucosal immune cell populations, could prove useful in identifying 
combinations of host immune factors influencing susceptibility to CDI. Of particular 
interest would be a study seeking to determine whether an association existed between 
the presence of the TLR SNPs and the character of the immune cell populations of the 
colonic lamina propria. Immunoglobulin class switching by B and plasma cells is 
mediated by the production of cytokines by cells of the innate immune system. If TLR-
mediated signalling upon recognition of C. difficile by these cells is altered by the 
presence of polymorphisms it may be reflected in the balance of IgG and IgA-secreting 
cells in the lamina propria.  
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Moxifloxacin resistant isolates carry a mutation in gyrA. All resistant isolates tested, 
with the exception of an isolate with intermediate resistance and a moxifloxacin mutant 
with reduced susceptibility, carried the common gyrA mutation ACT→ATT 
(Thr82→Ile). This mutation was not present in any sensitive isolates. Neither the 
intermediate isolate nor the moxifloxacin mutant carried any other gyrA mutation. No 
mutations in gyrB were found in any isolate. Semi-quantitative PCR analysis of 
expression of the putative efflux pumps cme and cdeA found no correlation between 
overexpression and moxifloxacin resistance, suggesting that these genes do not play a 
role in moxifloxacin resistance. Three novel mutations in the putative promoter region of 
CD3197, a MerR family transcriptional regulator found immediately upstream of cme, 
were identified. No association between the presence of these mutations and 
overexpression of cme or resistance or sensitivity to moxifloxacin was found.  
Although the data derived from semi-quantitative PCR did not ultimately support the 
hypothesis of a role for cme in moxifloxacin resistance, preliminary work on its 
expression strongly suggested that overexpression was seen in resistant isolates. There 
would be merit in looking further at this using the more sensitive and discriminatory 
technique of qPCR, possibly at a greater number of time points.  
The 19bp repeat sequence found in the putative promoter region of CD3197 appears to 
be unique to C. difficile. The data reported in this study suggest that variation in the 
number of repeat sequences is not associated with variability in transcription of cme. 
However, transcription is not the only process that may be affected by the presence of 
repeat sequences. Phenotypic variation in a number of bacterial species has been shown 
to be governed by variations in repeat sequence numbers that act as translational 
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switches (Moxon et al., 1994). This study did not look at translational differences 
between isolates and an analysis of cellular levels of the CD3197 protein could shed 
light on two questions. Firstly, do variations in the number of 19bp tandem repeats 
influence translation of these transcripts and secondly, does the relationship between 
levels of CD3197 and expression of cme indicate that CD3197 is indeed a transcriptional 
regulator of  cme.  
 
There is no difference in the fitness, as measured in terms of growth and toxin 
production, of moxifloxacin resistant and moxifloxacin sensitive isolates.  A 
comparison of the growth of resistant and sensitive isolates over a 24 hour period 
indicated that growth occurred more rapidly and to a higher level in sensitive isolates, 
however, the difference was not significant. A further study comparing the growth of a 
moxifloxacin mutant with reduced susceptibility and its sensitive parent isolate over a 
similar period showed that the mutant grew more rapidly and achieved higher OD values 
than did the parent, indicating that the fitness of the mutant was not impaired by its 
reduced susceptibility to moxifloxacin.  
 
A series of experiments examining toxin gene expression by means of semi-quantitative 
PCR demonstrated that there was no reproducible difference in the expression of tcdA 
and tcdB between resistant and sensitive isolates in late exponential/early stationary 
phase. Examination of toxin A and B production by ELISA showed that sensitive 
isolates have a greater interquartile range of OD values, however, median values were 
little different between sensitive and resistant isolates. 
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Appendix 1. Primer sequences and sources 
 
Gene Primer Sequence Source 
    











cdd-3 Tim 6 
 
5’-TCC AAT ATA ATA AAT TAG CAT TCC A-3’ 
 
Cohen et al., (2000) 
 Struppi 6 
 
5’-GGC TAT TAC ACG TAA TCC AGA TA-3’ 
 
 
cdtA F 5’-TGAACCTGGAAAAGGTGATG-3′  
 
Stubbs et al., (2000) 
 R 5′-AGGATTATTTACTGGACCATTTG-3′  
 
 
cdtB F 5′-CTTAATGCAAGTAAATACTGAG-3′  
 
Stubbs et al., (2000) 
 R 5′-AACGGATCTCTTGCTTCAGTC-3′  
 
 
cme F 5’-GCTGGTGTATGGGCAGACTA-3’ 
 
Designed with Primer 3 from 
published sequence of strain 630. 
 R 5’-CATTGCGTTTACAGCAGGTG-3’ 
 
 
gyrA GyrAF 5’-TTG AAA TAG CGG AAG AAA TGA-3’ 
 
Drudy et al., (2006). 
 GyrAR 5’-TTG CAG CTG TAG GGA AAT C-3’ 
 
 
gyrB GyrBF 5’-GAA GGT CAA ACT AAA ACA AA-3’ 
 
Drudy et al., (2006). 
 GyrBR 5’-GGG CTC CAT CTA CAT CAG-3’ 
 
 
IL-8  con 
 
5’-TGC CCC TTC ACT CTG TTA AC-3’ 
 
Hull et al., (2000) 
 251T 
 
5’-CCA CAA TTT GGT GAA TTA TCA AA-3’ 
 
 
 251A 5’-CCA CAA TTT GGT GAA TTA TCA AT-3’ 
 
 
 HLA-DRB1 F 5’-TGCCAAGTGGAGCACCCAA-3’ Internal control primer 
 HLA-DRB1R 5’- GCATCTTGCTCTGTGCAGAT-3’ Internal control primer 
Ribotyping F 5’-CTG GGG TGA AGT CGT AAC AAG G-3’ 
 
O’Neill et al., (1996) 
 R 5’-GCG CCC TTT GTA GCT TGA CC-3’ 
 
 
tcdA expression TA1 
 
5’-ATG ATA AGG CAA CTT CAG TGG-3’ 
 
Spigaglia & Mastrantonio (2002). 
 





TB1 5’-GAG CTG CTT CAA TTG GAG AGA-3’ 
 
Spigaglia & Mastrantonio (2002). 
 
 TB2 5’-GTA ACC TAC TTT CAT AAC ACC AG-3’ 
 
 
tcdA toxinotyping A3C 
 
TAT TGA TAG CAC CTG ATT TAT ATA CAA G 
 
Rupnik et al., (1997, 1998) 
 A4N 
 








tcdB toxinotyping B1C 
 
5’-AGA AAA TTT TAT GAG TTT AGT TAA TAG AAA-
3’ 
Rupnik et al., (1997, 1998) 
 B2N 
 
5’-CAG ATA ATG TAG GAA GTA AGT CTA TAG-3’ 
 
 
tcdC F 5’-GAGCCTTGTAACTGTTTATTTGC-3’ 
 
Designed with Primer 3 from 
published sequence of reference 
strain VPI10463 





F 5’-TAT GGT CCA GGA GCT GGA GA-3’ 
 
Ogus et al., (2004) 
 R 5’-TGA CAT AAA GAT CCC AAC TAG ACA A-3’ 
 
 
 G 5’-GGTCTTGGTGTTCATTATCTTCC-3’ 
 
 
 A 5’-GGTCTTGGTGTTCATTATCTTCT-3’ 
 
 
TLR5 F T5-11 
 
5' - GGTAGCCTACATTGATTTGC-3' 
 
Hawn et al., (2003) 
 R T5-23 
 
5' - GAGAATCTGGAGATGAGGTACCCG - 3' 
 
 
MerR F 5’-CACGACATCAGAGGTAGCAGA-3’ 
 
 
Designed with Primer 3 from 
published sequence of reference 
strain 630 
 R 5’-CAAGTGATGAGCCAAATAAGG-3' 
 
 
CD3197 F 5'-CGGTTATCTGTGGTGGCTATG-3' 
 
 
Designed with Primer 3 from 
published sequence of reference 
strain 630 
 R 5'-AGTGCTTCCTCGGCATTAGA-3' 
 
 
cdeA F 5'-TCACTGTTTTCAGCACCAAAA-3' 
 
Dridi et al., (2004) 






Appendix 2. Representative gels from the genetic polymorphisms study 




In this duplex reaction the internal control band is 470bp in length while the allele-
specific band is 328bp long. 
 
 
Lanes 1 and 20 100bp ladder; lanes 2 – 10 A allele and lanes 11-19 G allele, lanes 2 and 11 AW6; lanes 3 and 12 
AW31; lanes 4 and 13 AW75; lanes 5 and 14 AW81; lanes 6 and 15 AW31; lanes 7 and 16 AW82, lanes 8 and 17 
AW88; lanes 9 and 18 AW81; lanes 10 and 19 negative controls.  Where identification numbers are duplicated DNA 





The allele-specific band is 336bp in length. Primers were obtained for use in a duplex 
reaction to give an internal control band of 796bp. However, bands were not always seen 
for this reaction when allele-specific bands were present and non-specific bands were 
also observed. For these reasons certain PCR reactions were run without the control 






Lanes 1 and 20 100bp ladder; lanes 2 – 10 A allele and lanes 11-19 G allele, lanes 2 and 11 AW6; lanes 3 and 12 
AW31; lanes 4 and 13 AW75; lanes 5 and 14 AW81; lanes 6 and 15 AW31; lanes 7 and 16 AW82, lanes 8 and 17 
AW88; lanes 9 and 18 AW81; lanes 10 and 19 negative controls.  Where identification numbers are duplicated DNA 





The PCR product is 276bp in length. Variant alleles are identified by restriction digest 
using DdeI which cuts the variant allele only; the products of such a restriction have 





Lanes 1 and 16 100bp ladder; lane 2 AW57; lane 3 AW6; lane 4 AW7; lane 5 AW96; lane 6 AW97; lane 7 AW31; 
lane 8 AW81; lane 9 AW31; lane 10 AW95; lane 11 AW81; lane 12 AW21; lane 13 AW107; lane 14 AW108; lane 15 
AW95. Where identification numbers are duplicated DNA has been extracted from two different tissue samples from 
that individual.  
500bp 
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Clostridium difficile isolates (n5149) collected in south-east Scotland between August and
October 2005 were typed by four different methods and their susceptibility to seven different
antibiotics was determined. The aims were to define the types of strain occurring in this region and
to determine whether there were any clonal relationships among them with respect to genotype
and antibiotic resistance pattern. Ribotyping revealed that 001 was the most common type
(n5113, 75.8%), followed by ribotype 106 (12 isolates, 8.1%). The majority of the isolates
(96.6%, n5144) were of toxinotype 0, with two toxinotype V isolates and single isolates of
toxinotypes I, IV and XIII. PCR and restriction analysis of the fliC gene from 147 isolates gave two
restriction patterns: 145 of pattern VII and two of pattern I. Binary toxin genes were detected in
only three isolates: two isolates of ribotype 126, toxinotype V, and one isolate of ribotype 023,
toxinotype IV. S-types showed more variation, with 64.5% (n540) of the common S-type (4939)
and 21% (n513) of S-type 4741, with six other S-types (one to three isolates each). All ribotype
001 isolates were of the same S-type (4939), with three isolates of other ribotypes being this
S-type. No resistance was found to metronidazole or vancomycin, with resistance to tetracycline
only found in 4.3% of the isolates. A high proportion of isolates were resistant to clindamycin
(62.9%), moxifloxacin, ceftriaxone (both 87.1%) and erythromycin (94.8%). Resistance to three
antibiotics (erythromycin, clindamycin and ceftriaxone) was seen in 66 isolates, with erythromycin,
ceftriaxone and moxifloxacin resistance seen in 96 isolates. Resistance to all four of these
antibiotics was found in 62 isolates and resistance to five (the above plus tetracycline) in one
isolate: a ribotype 001, toxinotype 0 strain. Whilst ribotype 001 was the most commonly
encountered type, there was no evidence of clonal relationships when all other typing and
antibiotic resistance patterns were taken into account.
INTRODUCTION
Clostridium difficile is an anaerobic, Gram-positive, spore-
forming bacillus. It is commonly associated with a spec-
trum of disease referred to as C. difficile-associated disease
(CDAD), which can range from uncomplicated mild
diarrhoea to lethal toxic megacolon and possible colon
perforation (Johnson & Gerding, 1998). It is considered to
be the leading cause of nosocomially acquired diarrhoea in
adults and can be responsible for large outbreaks (Kelly &
LaMont, 1998). There is a view that the severity of the
disease is increasing. The new hypervirulent type (ribotype
027, toxinotype III, pulse-field NAP1) in North America
and several European countries has been associated with
more severe and fatal cases (McDonald et al., 2005; Kuijper
et al., 2006a; Hubert et al., 2007).
As elsewhere, C. difficile is rarely cultured in Scotland and
laboratory diagnosis depends on the detection of toxins A
and/or B in faeces. Several phenotypic and molecular
methods have been applied to determine the relatedness of
strains of C. difficile. All have their advantages and
disadvantages. Methods based on whole-genome analysis
are more discriminatory, but they are technically demand-
ing and labour-intensive (Brazier, 2001). PCR ribotyping is
commonly used in Europe as it has been reported to beAbbreviation: CDAD, Clostridium difficile-associated disease.
3Present address: Antalya Atatürk Devlet Hastanesi, Mikrobiyoloji ve
Klinik Mikrobiyoloji Bölümü, Üçgen mevkii, 07040 Antalya, Turkey.
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highly discriminative, reproducible, relatively rapid and
easy to perform (O’Neill et al., 1996; Stubbs et al., 1999).
Toxinotyping is a PCR-RFLP method that depends on
changes in the toxin genes and other regions of the
pathogenicity locus of C. difficile. It has been reported to
correlate well with restriction endonuclease analysis,
serotyping and PCR ribotyping and it also gives the
advantage of determining toxin variant strains (Rupnik et
al., 1998; Johnson et al., 2003). Flagellin gene RFLP analysis
has been described as an additional typing method that can
be used in conjunction with other typing methods
(Tasteyre et al., 2000).
An actin-specific ADP-ribosylating binary toxin CDT is
produced by some strains of C. difficile. Its role in
pathogenesis is currently unclear, but its presence has been
correlated with severity of disease in some studies (Barbut
et al., 2005) and it is present in the 027 hypervirulent strain
(McDonald et al., 2005). The prevalence of binary toxin in
clinical isolates of C. difficile is generally low, with
frequencies ranging between approximately 2 and 20%
(Barbut et al., 2005).
The aims of this study were to (i) characterize 149 C.
difficile isolates from toxin-positive faecal samples collected
between August and October 2005 by molecular typing
methods, PCR ribotyping, toxinotyping and flagellin gene
RFLP analysis and by the S-layer typing method, together
with the detection of the binary toxin genes cdtA and cdtB;
and (ii) determine the susceptibility of isolates to seven
different antibiotics. The objectives were to show which
strains were currently present locally, to determine whether
there were any clonal relationships between isolates and to
examine the antimicrobial susceptibility profiles of the
different types.
METHODS
Bacterial isolates. C. difficile isolates (n5149) from toxin-positive
faecal samples (determined using a Toxin A+B ELISA kit; TechLab)
were collected between August and October 2005 and stored at
220 uC. All specimens were from different unselected cases of CDAD
in different hospitals in the Edinburgh area (Lothian University
Hospitals National Health Service Trust) consisting of acute and
long-stay hospitals. They were collected on a purely random basis
with no selection for hospital or patient type. During this period, we
were not aware of any outbreaks. Stool samples were cultured on
Brazier’s cefoxitin/cycloserine/egg yolk agar (LabM) and incubated
for 48 h at 37 uC in an anaerobic chamber. The isolates were identified
by characteristic colony morphology, smell, fluorescence under long-
wave UV light and appearance on a Gram film. Subcultures were
stored in anaerobic investigation medium containing cooked
meat particles for maintenance (Brown et al., 1996). Control strains
were NCTC 11223, VPI 10463, 338a (a locally isolated strain of
ribotype 01; McCoubrey, 2002), the sequenced strain 630 and a 027
strain from Amsterdam provided by E. Kuijper (Leiden, The
Netherlands).
DNA extraction. Colonies from overnight anaerobic cultures on
fastidious anaerobe agar (LabM) supplemented with 6% horse blood
were resuspended in 100 ml of a 5% solution of Chelex-100 resin
(Bio-Rad). After incubating in a boiling bath for 10 min, the cell
debris was removed by centrifugation for 2 min at 18 000 g. The
supernatant was used as the crude DNA template for PCRs except for
toxinotyping.
For toxinotyping, pure DNA isolation was required. DNA was
extracted using a Nucleospin Tissue kit (Macherey-Nagel) according
to the manufacturer’s instructions.
PCR ribotyping. All 149 isolates were typed by PCR ribotyping
according to the method described by O’Neill et al. (1996). Specific
oligonucleotide primers 59-CTGGGGTGAAGTCGTAACAAGG-39
(nt 1445–1466 of the 16S rRNA gene) and 59-GCGCCCTTTGTA-
GCTTGACC-39 (nt 20–1 of the 23S rRNA gene) complementary to
the 39 end of the 16S rRNA gene and the 59 end of the 23S rRNA gene
were used to amplify the variable-length intergenic spacer region. The
338a and 027 strains were used as controls for ribotypes 001 and 027.
Patterns that were different from these two ribotypes were compared
with the library of PCR ribotypes already established at the Anaerobe
Reference Unit, Cardiff, UK.
Toxinotyping. All 149 isolates were subjected to toxinotyping by the
methods developed by Rupnik et al. (1997, 1998). The first 3 kb of
tcdB (PCR fragment B1) and the 3 kb repetitive region of tcdA (PCR
fragment A3) were detected and characterized by RFLP. The primers
59-AGAAAATTTTATGAGTTTAGTTAATAGAAA-39 and 59-CAG-
ATAATGTAGGAAGTAAGTCTATAG-39 for the B1 fragment and
59-TATTGATAGCACCTGATTTATATACAAG-39 and 59-TTATC-
AAACATATATTTTAGCCATATATC-39 for the A3 fragment were
used as described by Rupnik et al. (1997). PCRs were performed in a
final volume of 50 ml with a reaction mixture containing 20 mM Tris/
HCl (pH 8.3), 50 mM KCl, 1% W-1, 3 mM MgCl2, 1 U Taq
polymerase (Invitrogen), 200 mM each dNTP, 15 pmol each primer
and 5 ml template DNA. For amplification of A3 fragments,
tetramethylammonium chloride (Sigma) was added to a final
concentration of 1024 M. After initial denaturation at 93 uC for
3 min, B1 products were amplified for 30 cycles and A3 products for
35 cycles of annealing and extension at 47 uC for 8 min and
denaturation at 93 uC for 4 s. Final extension was at 47 uC for 10 min.
Amplified fragments were visualized on a 1% agarose gel and
subjected to restriction enzyme digestion using the restriction
enzymes AccI, HincII (B1) and EcoRI (A3). After electrophoresis of
the digestion products, the toxinotypes of all tested isolates were
determined using the toxinotyping schema described by Rupnik et al.
(1997, 1998).
Detection of binary toxin genes. The presence of binary toxin
genes among all 149 study isolates was detected by PCR as described
by Stubbs et al. (2000). Primers designed to amplify the genes
encoding the enzymic (cdtA) and binding (cdtB) components of the
binary toxin were as follows: CDTA-F, 59-TGAACCTGGAAAAGG-
TGATG-39; CDTA-R, 59-AGGATTATTTACTGGACCATTTG-39;
CDTB-F, 59-CTTAATGCAAGTAAATACTGAG-39; CDTB-R, 59-
AACGGATCTCTTGCTTCAGTC-39. The 027 strain, which is known
to produce binary toxin, was used as the positive-control strain. The
product sizes for cdtA and cdtB were 375 and 510 bp, respectively.
PCR-RFLP analysis of the flagellin (fliC) gene. The fliC gene of
147 of the study isolates (two were lost) was amplified using the
specific primers Nter (59-ATGAGAGTTAATACAAATGTAAGTGC-
39) and Cter (59-CTATCCTAATAATTGTAAAACTCC-39) corre-
sponding to the 59- and 39-end sequences of the fliC gene of C.
difficile (Tasteyre et al., 2000). Amplification was carried out in a final
volume of 50 ml reaction mixture containing 20 mM Tris/HCl (pH
8.3), 50 mM KCl, 2 mM MgCl2, 1 U Taq polymerase (Promega),
0.2 mM each dNTP, 1 mM each primer and 5 ml template DNA.
Initial denaturation was carried out at 94 uC for 5 min, followed by
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35 cycles of denaturation at 94 uC for 30 s, annealing at 55 uC for 30 s
and extension at 72 uC for 1 min. A final step of extension for 10 min
at 72 uC was performed. Products of 870 bp were digested with the
restriction enzymes HpaI, HindIII and RsaI. Digested products were
electrophoresed on a 1.2 % agarose gel to determine their RFLP
groups. The restriction enzyme HincII was used for further diffe-
rentiation between group I and group III flagella types.
S-layer typing. The S-layer typing of C. difficile isolates was per-
formed as described previously (McCoubrey et al., 2003). Briefly, the
isolates were subcultured and S-layer proteins were extracted with 5
M guanidine hydrochloride. The resulting two major and several
minor bands were visualized by SDS-PAGE (Invitrogen) with
Coomassie staining. Mark 12 molecular mass standards were used
as calibrations for the calculation of molecular masses. Banding
patterns were compared with the previous types.
Antibiotic susceptibility testing. The MICs of 116 of the isolates
for six antibiotics were determined using the agar dilution protocol in
the NCCLS guidelines (NCCLS, 2001). The antibiotics and concen-
trations used were as follows: 16–0.125 mg ml21 for vancomycin,
32–0.5 mg ml21 for metronidazole, 256–4 mg ml21 for ceftriaxone,
32–0.5 mg ml21 for clindamycin, 32–0.5 mg ml21 for erythromycin
and 64–1 mg ml21 for tetracycline (all from Sigma). The isolates were
subcultured from cooked meat broth into pre-reduced thioglycollate
medium (Sigma) enriched with 5 mg haemin, 1 mg vitamin K1 and
1 mg NaHCO3 ml
21 and incubated overnight in an anaerobic
chamber at 37 uC. After adjusting the turbidity to a 0.5 McFarland
standard, aliquots (1–2 ml) of the cultures were spotted onto Brucella
agar (Oxoid) supplemented with haemin, vitamin K1 and 5% lysed
horse blood plus antibiotic of a given concentration using a
multipoint inoculator and incubated anaerobically at 37 uC for 48 h.
Control plates were also inoculated and incubated aerobically to
check for aerobic growth. Strains NCTC 11223, 338a and 630 were
used as control strains as their MICs were known from our previous
study (Drummond et al., 2003).
The MICs of the isolates for moxifloxacin were determined by the
Etest (AB Biodisk) as we were unable to obtain the pure substance
from Bayer. The isolates were grown in pre-reduced thioglycollate
medium (Sigma) enriched with 5 mg haemin, 1 mg vitamin K1 and
1 mg NaHCO3 ml
21 and incubated overnight in an anaerobic
chamber at 37 uC. The Etest was carried out by inoculating the surface
of pre-reduced fastidious anaerobe agar (LabM) plates containing
vitamin K1, haemin and 5% lysed horse blood with a 1 McFarland
standard-matched inoculum. The inoculation was performed with
cotton-tipped swabs and Etest strips were applied to the agar surface
according to the manufacturer’s instructions. Sufficient growth was
obtained after 24 h and the ellipse was clearly visible. The end points
were read at complete inhibition of all growth, including hazes and
isolated colonies. Strains 630 and 027 were used as sensitive and
resistant controls, respectively.
Breakpoints of susceptibility for each drug were chosen at the levels
listed by the NCCLS. MIC50 and MIC90 values for each isolate were
calculated using Microsoft EXCEL.
RESULTS AND DISCUSSION
Molecular typing
The 149 isolates included in this study were collected over a
period of 2 months between August and October 2005. The
results of the different typing methods are summarized in
Table 1. All of the isolates were typable by the PCR
ribotyping method and 15 different ribotype patterns could
be discriminated. Ribotype 001 was the most common
(n5113, 75.8%), followed by ribotype 106 with 12 isolates
(8.1%). The other ribotypes identified were 005 and 014
with four isolates each, ribotype 002 with three isolates and
ribotypes 013 and 126 with two isolates, whilst the other
ribotypes (020, 023, 042, 049, 070, 171) were represented
by single isolates. Three isolates belonging to two different
ribotypes were not able to be allocated a specific ribotype
and may represent new types. No 027 strain was found.
However, during the preparation of this manuscript the
first case of 027 in Scotland was reported from the Glasgow
area. These findings are consistent with other reports from




Different toxinotypes found for each ribotype Different fliC patterns for
each ribotype
0 I IV V XIII I VII
001 (113)* 111 1 – – 1 – 112
106 (12)* 12 – – – – 1 10
005 (4) 4 – – – – – 4
014 (4) 4 – – – – – 4
002 (3) 3 – – – – – 3
013 (2) 2 – – – – – 2
126 (2) – – – 2 – – 2
020 (1) 1 – – – – – 1
023 (1) – – 1 – – – 1
042 (1) 1 – – – – 1 –
049 (1) 1 – – – – – 1
070 (1) 1 – – – – – 1
171 (1) 1 – – – – – 1
Others (3) 3 – – – – – 3
*One isolate from each of these ribotypes could not be typed by fliC restriction analysis.
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the UK prior to the recognition of the 027 strains in several
areas of England. PCR ribotype 001 has been reported to be
the most common type (55%) among hospitalized patients
in the UK (Stubbs et al., 1999). In an earlier study by our
group, ribotype 001 was responsible for 78% of CDAD
infections locally (McCoubrey et al., 2003). Recently,
ribotype 106 has become prominent in England. In the
period 1995–2003 it was at similar levels to those found in
our study (8%); however, in 2005 it was the predominant
strain at 26%, just above 027 strains and surpassing the
001 strains, which were both at 25% (Health Protection
Agency, 2006). Prior to the recognition of 027 strains in
Europe, particularly in The Netherlands and Belgium, there
are only a few reports from other countries in Europe. In a
Polish hospital, all environmental isolates and 11 of 31
neonatal isolates were found to belong to ribotype 001
(Martirosian et al., 1995), whereas ribotype 087 accounted
for 39% of all isolates in Hungary (Urban et al., 2001). In
one report from the Middle East, ribotypes 097 and 078
were reported to be responsible for over one-third of the
cases of CDAD in Kuwaiti hospitals (Rotimi et al., 2003).
All of the isolates were subjected to toxinotyping. The B1
and A3 fragments of tcdA and tcdB were amplified as they
have been reported to be the most variable fragments and
good markers when searching for variant strains (Rupnik,
2001). C. difficile VPI 10463 (which has been defined as
toxinotype 0; Rupnik et al., 1998) was used as a reference
strain. This toxinotype 0 was observed in the majority of
the isolates (96.6%, n5144). The five remaining isolates
were of four different known toxinotypes: toxinotypes I, IV
and XIII with one isolate each and toxinotype V with two
isolates. No toxinotype III strains were found. There was
no previous local information on the prevalence and
distribution of different toxinotypes. When compared with
the studies from Europe, the rates of variant (not 0)
toxinotypes in our study were lower (Rupnik et al., 1998,
2001; Spigaglia & Mastrantonio, 2002). The profiles of the
strain collections in these studies were different but non-
toxigenic strains were not included in our study. The
prevalence of variant toxinotypes has been reported to be
21.5% among the selected C. difficile isolates from 22
serogroups tested by Rupnik et al. (1998) and was
estimated for the Cardiff collection as 8.8% among the
toxinogenic strains (Rupnik et al., 2001). The percentage of
variant strains from Asia has been reported to be 23.5%,
whilst 25% of the toxinogenic strains from Italy were
found to show variation (Spigaglia & Mastrantonio, 2002;
Rupnik et al., 2003a). Of the strains from an American
hospital, 11.1% belonged to variant toxinotypes. The most
frequent variant toxinotypes in two European collections
were toxinotypes III, IV and VIII (Rupnik et al., 1998,
2001). Our variant strains were of toxinotypes I, IV, V and
XIII. The toxinotype IV strain was of ribotype 023, whilst
two toxinotype V strains were of ribotype 126. Toxinotypes
I and XIII were of ribotype 001. In our study, among the
15 ribotypes that were determined, all isolates within
a ribotype except ribotype 001 belonged to a single
toxinotype. This was similar to the findings of Rupnik
et al. (2001) where PCR ribotyping and toxinotyping were
shown to correlate well. In the case of different toxinotypes
within a PCR ribotype, these toxinotype profiles were
found to be similar. In our study, only five isolates of
toxinotypes other than 0 were found and isolates of
ribotype 001 belonged to three different toxinotypes.
Toxinotype I and XIII strains have been reported to differ
from toxinotype 0 only at the 39 end of the tcdA gene
(Rupnik et al., 1998).
PCR amplification of the fliC gene from 147 isolates
produced an 870 bp fragment. Two different restriction
profiles were obtained when the amplification products
were digested using the enzymes HpaI, HindIII and RsaI.
All isolates but two were of restriction pattern VII, the
exceptions being restriction pattern I, and were of
ribotypes other than 001 (ribotypes 106 and 042) but were
of toxinotype 0. Tasteyre et al. (2000) compared PCR-
RFLP analysis of the flagellin gene and serogroups in a
collection of strains representing all of the 12 known
serotypes from widely different geographic areas. They
reported that this method could constitute an additional
typing method to be used in conjunction with other
methods. They found RFLP type VII as the most frequent
RFLP type, followed by types I and VIII. RFLP type VII
strains were mostly toxin-positive strains, whereas type I
strains were either toxin positive or negative. They found
that RFLP types II, III, IV, V and VI were uncommon and
only associated with single serogroups. Our study is the
first to compare ribotyping and toxinotyping with flagellin
gene typing. However, only two flagella types were detected
(I and VII): type VII strains contained different ribotypes
and toxinotypes and type I strains were of different
ribotypes but all of toxinotype 0. Thus a larger number
of strains from different ribotypes and toxinotypes are
needed to be able to determine the relationships between
these typing methods.
All strains (n5149) were tested for the presence of binary
toxin genes (cdtA and cdtB), but only three (2%)
harboured these genes. Similar to the number of variant
strains encountered above, the presence of binary toxin
genes was low compared with other studies. It has been
reported that 6.4% of toxigenic isolates of C. difficile
referred to the Anaerobe Reference Unit from UK hospitals
had both binary toxin genes (Stubbs et al., 2000) and 4.5,
5.8 and 8.6% prevalence of binary toxin-positive strains
was detected in Spain, America and Poland, respectively
(Geric et al., 2004; Alonso et al., 2005; Pituch et al., 2005).
Pituch et al. (2005) found that all binary toxin-positive
strains from Poland were of the same toxinotype, type IV,
and were all of the same ribotype. In our study, two of
the binary toxin-positive isolates were of ribotype 126,
toxinotype V, and one isolate belonged to ribotype 023,
toxinotype IV. In most studies, it has been shown that only
strains belonging to variant toxinotypes that have sig-
nificant changes in tcdA and tcdB possess binary toxin
genes (Stubbs et al., 2000; Rupnik et al., 2003b). Geric et al.
E. Mutlu and others
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(2003) reported A2B2 strains with binary toxin genes. We
had only toxigenic strains in our study. Our strains of
toxinotypes IV and V with changes in both the tcdA and
tcdB genes had binary toxin genes, whereas strains of
toxinotypes I and XIII with minor differences only in the 39
end of the tcdA gene did not have cdtA or cdtB.
S-layer typing
In the past, we have used S-typing as our primary method
for epidemiological studies of C. difficile (McCoubrey et al.,
2003). We were interested in correlating the different
molecular types with S-type. However, as it is relatively
labour-intensive, we selected a sample of only 62 isolates to
represent the range of molecular types described above
with the result that six different S-types were recognized.
Most isolates (64.5%; n540) belonged to the common S-
type, known as type 4939, named for the molecular masses
of the two S-layer peptides. In an earlier paper (McCoubrey
et al., 2003), this common S-type, which is that of ribotype
001, was referred to as 5336. We have recently changed our
SDS-PAGE system to a commercial system (Invitrogen)
employing 10% gels. With this new method, the molecular
masses of the S-layer proteins are found to be different.
Most of the others were of S-types 4741 (21%; n513) and
4640 and 4938 with three isolates each (4.8%). Of the
remainder, two isolates (3.2%) were of S-type 4639 and
one isolate (1.6%) was of S-type 4837. All ribotype 001
isolates (n537) were of the same S-type (4939), whilst
three of the isolates from different ribotypes were also of
this S-type. All but one of the ribotype 106 isolates (n511)
were of S-type 5242, the other being of the common 4939
type. Ribotypes 002 and 014 also contained different S-
types. The toxinotype 0 isolates (n559) belonged to all six
S-types, with the most common being S-type 4939 (n538).
Toxinotype I and XIII isolates, which were also of ribotype
001, were of S-type 4939.
The discriminatory power of different typing methods is
an important consideration when selecting which method
to use. The usual gold standard of PFGE is generally
considered to have a higher degree of discrimination than
PCR ribotyping. However, in the past, the typing ability of
PCR ribotyping was higher than that of PFGE because
DNA degradation occurred as a result of endogenous
restriction enzymes in strains from serogroup G, which
corresponds to PCR ribotype 001 (Collier et al., 1996; Bidet
et al., 2000).
Currently, PCR ribotyping is preferred because of the ease
and speed of the technique and because it is reported to be
highly discriminatory and reproducible. Toxinotypes are
reported to correlate well with the types obtained by two
other typing schemes, serogrouping and PFGE typing
(Rupnik et al., 1998), whilst toxinotyping and ribotyping
methods correlate well. Most strains within a PCR ribotype
belonged to a single toxinotype. Strains in toxinotypes I,
III, IV, VI and VIII could be differentiated into several PCR
ribotypes (Rupnik et al., 2001).
Antibiotic susceptibility testing
A major aim of this study was to determine the current
antibiotic susceptibility patterns of the C. difficile isolates
in our region and to find out whether there was any
relationship between the types and antibiotic susceptibil-
ities. The susceptibility to antibiotics was investigated in a
sample of 116 isolates of our collection by determining the
MICs for seven antibiotics: metronidazole, vancomycin,
erythromycin, clindamycin, ceftriaxone, moxifloxacin and
tetracycline. Table 2 shows the ranges of MICs and resi-
stance rates among the isolates for the seven antibiotics used,
together with MIC50 and MIC90 values and breakpoints for
the antibiotics. All isolates were sensitive to the two agents
commonly used to treat CDAD, metronidazole and
vancomycin, with a narrow range of MICs.
In our previous study (Drummond et al., 2003), no
resistance to metronidazole or vancomycin was reported.
MIC ranges and MIC50 and MIC90 values for these
antibiotics were similar to those in the present study.
However, the number of isolates with an MIC of 4 mg ml21
for vancomycin increased from 5 out of 186 isolates
(2.7%) in our earlier study to 25 out of 116 isolates
(21.6%) in the present study. Vancomycin and metroni-
dazole are the most common antibiotics used in the
treatment of CDAD and, in most studies, isolates of C.
difficile have generally been found to be susceptible to these
(Drummond et al., 2003; Aspevall et al., 2006). However, a
few studies have reported strains resistant to metronidazole
or with reduced susceptibility to vancomycin (Brazier et al.,
Table 2. Range of MIC values and resistance rates from 116 isolates with the breakpoints used
Antibiotic MIC range (mg ml”1) MIC50 (mg ml
”1) MIC90 (mg ml
”1) Breakpoint (mg ml”1) Resistance (%)
Vancomycin 1–4 2 4 ¢8 0
Metronidazole ¡0.5–4 1 2 ¢8 0
Erythromycin 0.5–¢32 ¢32 ¢32 ¢8 94.8
Clindamycin 0.5–¢32 8 16 ¢8 62.9
Ceftriaxone 32–256 64 64 ¢64 87.1
Moxifloxacin 0.25–¢32 ¢32 ¢32 ¢4 87.1
Tetracycline ¡1–64 ¡1 2 ¢16 4.3
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2001; Peláez et al., 2005). The first UK isolate of C. difficile
with reduced susceptibility to metronidazole was reported
in 2001 (Brazier et al., 2001).
Resistance to clindamycin was seen in 73 isolates (62.9%).
Tetracycline resistance was low, with only five isolates with
MICs ¢16 mg ml21. MIC50 and MIC90 values for erythro-
mycin were ¢32 mg ml21, showing that the majority of the
isolates were highly resistant to this antibiotic (n5110,
94.8%). Similar high resistance rates to the antibiotics
ceftriaxone and moxifloxacin (87.1%) were also found.
Their MIC50 values were high and the same as their MIC90
values.
Previously, moxifloxacin was reported to have good
activity against Gram-positive bacilli including C. difficile
(Hoogkamp-Korstanje & Roelofs-Willemse, 2000), but
reduced susceptibility to this antibiotic has been shown
in several studies (Wilcox et al., 2000; Leroi et al., 2002).
Clindamycin and ceftriaxone resistance rates did not show
much difference from our previous study (Drummond
et al., 2003).
Antibiotic susceptibility in relation to molecular
type
Of the 116 isolates for which MICs were measured, 87 were
of ribotype 001, 10 were of ribotype 106 and 19 were of
other ribotypes. In terms of toxinotype, 112 were of
toxinotype 0, with one isolate each of toxinotypes I, IV, V
and XIII. The antibiotic resistance patterns of these
116 isolates are detailed in Table 3.
In a study from the UK, PCR ribotypes 001 and 106 were
found to be more resistant to erythromycin (98 and 100%,
respectively) than other PCR ribotypes (John & Brazier,
2005). All of our ribotype 001 and 106 ribotypes were
resistant to this antibiotic. We also found higher resistance
levels to the antibiotics ceftriaxone and moxifloxacin,
which were not tested in that study, among ribotype 001
and 106 isolates than among the other ribotypes. John &
Brazier (2005) reported that clindamycin resistance was
lower than erythromycin resistance in ribotypes 001 and
106, whilst ribotypes 015, 014, 005 and 002 had a higher
frequency of resistance to clindamycin than to erythro-
mycin. Of our isolates, only ribotype 002 had a higher
clindamycin resistance level than erythromycin, but the
frequency of clindamycin resistance was lower for ribotype
014, whilst both resistance rates were the same for ribotype
005. In a study in which clindamycin and fusidic acid
resistances were determined (Aspevall et al., 2006), no
particular relationship between PCR ribotypes and anti-
biotic resistance was found. The clindamycin resistance
frequency in our study was lower than that found by
Aspevall et al. (2006) (83%). In a study from Australia, the
MIC range for moxifloxacin (0.75 to .32 mg ml21) was
found to be close to the resistance breakpoint with MIC50
and MIC90 values of 2 and 4 mg ml
21, respectively (Leroi
et al., 2002). Susceptibilities of clonal and distinct C. difficile
strains from the UK to newer fluoroquinolones including
moxifloxacin have been tested (Wilcox et al., 2000).
Trovafloxacin and moxifloxacin were the most active
fluoroquinolones with three- to fourfold more activity than
older agents such as ciprofloxacin among genotypically
distinct strains. Clonal strains that were epidemic ribotype
001 strains were sevenfold less susceptible to moxifloxacin
compared with the distinct strains. The MIC range for this
antibiotic was 0.12–16 mg ml21 andMIC50 andMIC90 values
were 1 and 16 mg ml21, respectively (Wilcox et al., 2000). We
found higher MIC50 and MIC90 values for moxifloxacin
in our study. Most of the ribotype 001 (98.9%, n586)
and ribotype 106 (90%, n59) isolates were resistant to
moxifloxacin, whereas only six isolates (31.5%) from other
ribotypes were resistant in our study.
Only two isolates of flagellin gene restriction pattern I were
observed. All of these restriction type I isolates were
sensitive to tetracycline and moxifloxacin and resistant to
erythromycin. One was resistant to both clindamycin and
Table 3. Percentage antibiotic resistance rates by ribotype and toxinotype
Antibiotic Percentage of isolates resistant to antibiotics based on:
Ribotype Toxinotype
001 (n587) 106 (n510) Other (n519) 0 (n5112) I (n51)* IV (n51)* V (n51)* XIII (n51)*
Erythromycin 100 100 68.4 95 R S R R
Clindamycin 62.1 70 63.1 62.5 R S R R
Ceftriaxone 95.4 100 42.1 87.5 R R S R
Moxifloxacin 98.9 90 31.5 88.3 R S S R
Tetracycline 1.2 0 21.1 3.57 S S R S
Metronidazole 0 0 0 0 S S S S
Vancomycin 0 0 0 0 S S S S
*As toxinotypes I, IV, V and XIII are represented by single isolates, the designations R (resistant) and S (sensitive) have been used rather than
percentages.
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ceftriaxone, whilst the other was sensitive to both
antibiotics.
One of the two isolates carrying the binary toxin genes was
resistant to erythromycin, clindamycin and tetracycline,
whilst the other one was only resistant to ceftriaxone. Both
isolates were sensitive to moxifloxacin.
Fifty-six of the 62 isolates that were typed by S-layer were
tested for antibiotic susceptibility. Most of the S-type 4939
isolates (38/39) and all of the S-type 4741, 4938 and 4639
isolates (n510, n53 and n52, respectively) were resistant
to erythromycin. Most of the S-type 4939 and 4741 isolates
were resistant to clindamycin, ceftriaxone and moxiflox-
acin. One isolate that belonged to S-type 4837 was sensitive
to all antibiotics. This isolate was of ribotype 070, toxino-
type 0 and fliC restriction type VII.
Multi-resistant strains
Seventy-two isolates were resistant to both erythromycin
and clindamycin in our study, with resistance to both
antibiotics being 62, 70 and 52.6% in ribotypes 001, 106
and the others, respectively. Of toxinotype 0 and other
toxinotype isolates, 61.6 and 75% were resistant to both
antibiotics, respectively. Only one fliC restriction pattern I
isolate and one binary toxin gene-positive isolate resistant
to these antibiotics were encountered. Macrolide–lincos-
amide–streptogramin B resistance in C. difficile is mostly
encoded by the ermB resistance determinant. This gene
encodes a 23S rRNA methyltransferase that modifies the
target site for the antibiotic and is a mobilizable,
conjugative transposon, Tn5398 (Farrow et al., 2001). In
recent years, some ermB-negative isolates with erythro-
mycin and clindamycin resistance have been reported
(Ackermann et al., 2003; Spigaglia & Mastrantonio, 2004;
Pituch et al., 2006). Spigaglia & Mastrantonio (2004) could
not find any erm genes of other classes such as ermA, ermC,
ermF, ermQ and mefA among these isolates. It has been
suggested that resistance in ermB-negative resistant strains
could be due to mutations within the target sequences in
the 23S rRNA or efflux mechanisms or a new mechanism
of resistance (Ackermann et al., 2003; Spigaglia &
Mastrantonio, 2004; Pituch et al., 2006). We did not test
our isolates for resistance genotypically.
A total of 66 isolates were resistant to the three antibiotics
erythromycin, clindamycin and ceftriaxone and 96 isolates
were resistant to erythromycin, ceftriaxone and moxiflox-
acin. Ribotypes 001 and 106 had higher resistances (95.4
and 90%, respectively) to the antibiotics erythromycin,
ceftriaxone and moxifloxacin when compared with other
PCR ribotype groups (21%). Ackermann et al. (2001)
suggested that resistance to moxifloxacin might be due to
amino acid substitution in the DNA gyrase. They also
found that moxifloxacin-resistant strains that were selected
in vitro had wild-type gyrA sequences.
In our study, only one isolate was resistant to five
antibiotics: erythromycin, clindamycin, moxifloxacin,
ceftriaxone and tetracycline; it was of ribotype 001 and
toxinotype 0. Ackermann et al. (2003) reported resistances
to the antibiotics erythromycin, clindamycin and moxi-
floxacin as 27, 36 and 12%, respectively, among 192
isolates tested. They found that moxifloxacin resistance was
almost always detected together with resistance to ery-
thromycin and clindamycin (12.5%). In our study, 110
erythromycin-resistant isolates were found of which 100
(90.9%) were resistant to moxifloxacin and only one out of
six erythromycin-sensitive isolates was resistant to moxi-
floxacin. Among the 73 clindamycin-resistant isolates, 64
(87.7%) were also resistant to moxifloxacin. Of the
72 isolates resistant to both erythromycin and clindamycin,
64 (88.9%) were resistant to moxifloxacin. Additionally,
we found that all but one of the 64 isolates that were
resistant to these three antibiotics were also resistant to
ceftriaxone and these multi-resistant isolates were mostly
of ribotype 001 (n553, 84.1%).
As the 027 type has a characteristic antibiotic resistance
pattern – resistant to erythromycin, susceptible to clin-
damycin and resistant to moxifloxacin (Kuijper et al.,
2006b) – this could be part of an algorithm to identify 027
strains. However, in our study we identified 36 strains that
were resistant to erythromycin, susceptible to clindamycin
and resistant to moxifloxacin. Thirty-two of these strains
were of ribotype 001, three were of ribotype 106 and one
was of 014, and all of them were of toxinotype 0. This
questions the usefulness of this approach to detect 027
strains.
We are aware that a Europe-wide surveillance study has
been performed (F. Barbut and others, unpublished) and
some strains for this study were collected in Scotland.
However, there was no overlap in strains between these
studies as those for the European surveillance study were
collected earlier in 2005.
The results obtained from this study demonstrate clearly
the complexity of the strains of C. difficile in our area. If
characterized purely on ribotyping, it would appear that
most of the strains are closely related. However, the use of
other typing methods, especially antibiotic resistance
patterns, demonstrates wide variation among strains.
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